n n u l r e p r march shareholders alex gorsky chairman chief executive officer ive worked health care industry rather true innovations result united nearly years honor collaboration collaboration inspired privilege work johnson johnson driven diversity ideas individuals credo company touches lives disciplines working together toward rings billion people every day around common goal true today world look todays health care landscape incredibly clear today ever world needs written pace change never greater leaders committed working frankly exciting together help bring improved health years ago wellness every person every todays rapid change brings corner globe worlds largest opportunities risks company broadly based health care health care prepared company uniquely positioned help address significant transform global health care shine light challenges overcome tools important issues facing insights technologies innovations collaborate across boundaries evolutions revolutions borders uncover scientific insights combine make today one ideas dedicate resources towards promising times human health creating tomorrows breakthroughs johnson johnson united inspired credo years company rings true today inventing future health care written years ago beginning learned innovation reminds us first responsibility seldom product solitary genius customers patients chairmans letter icompels us deliver responsibilities worlds largest comprehensive employees communities health care company one better environment shareholders positioned johnson johnson lead important work strong foundation continue use breadth addition commitment advance comprehensively advance human health health comprehensively also employ invest enduring longterm impact disciplined portfolio management position businesses deliver strong ensure focused solving consistent sustainable results important medical consumer hold accountable health needs investing promising future responsibilities put people first growth areas businesses continue meeting expectations advancing human health completed acquisitions believe business significant licensing deals well eight put patient broadly based health care divestitures positioning us continued center continue major profitable growth reward factor success allowed us innovations deliver strong consistent growth acquisition abbott medical optics drive well return significant value closed early excellent better shareholders throughout various example flexibility invest areas outcomes economic cycles opportunity across spectrum longterm health care consumer expertise value companys structure also allows us particularly vision care space interconnect breadth depth combined medical device drive innovation take advantage expertise made opportunity uniquely growth opportunities wherever may complementary portfolio across dynamic health industry excited adding strong particularly important industry differentiated surgical ophthalmic offering continues evolve political particularly cataract surgery environment poses new challenges vision care business coupled opportunities incredibly worldleading acuvue contact lens clear emerging area healthtech business help us become broad potential intersection based leader vision care transaction technology health care completely excellent example approach change disrupt existing health care acquisitions right deal ecosystem never imminent right time right price new healthtech space becoming drive growth create value integral everything shareholders ii chairmans letterour broad base across health care investing longterm strong global footprint also gives us unique growth insight opportunities work way driven broad governments health care systems save improve lives base human around world influence investments clear perspective imperatives health care health volatility see financial performance objective extends emerging markets health care cost johnson johnson grow sales reach challenges exist developed organically faster rate market capabilities emerging markets clearly demonstrate grow earnings faster sales strategic importance advocating improved objective met advantages access quality health care well patients rewards innovations drive better additionally focus strong providers outcomes longterm value cash flow ensures able make consumers continue leading voice appropriate investments around discussions advocating solutions business capitalize right world best interests health opportunities create greater longterm wellness patients consumers value shareholders start funding internal growth initiatives including investments research development b rd investments totaled funding organic growth billion strategic capital allocation framework outlines use remaining free cash flow b free first priority delivering competitive cash flow dividend shareholders billion increased consecutive years b paid billion dividends meeting dividend goals target value creating acquisitions b invested approximately billion finally consider prudent ways acquisitions major return value shareholders licensing deals share repurchase programs b completed twothirds billion share repurchase program chairmans letter iiiour total shareholder return expect key catalysts strong significantly exceeding growth include competitor composite well continued strong performance exceeding major indices including inline products increasing penetration sp true markets anticoagulants im proud say also case psoriasis longacting antipsychotics last three five ten twenty year capitalizing early launch success periods historically approximately key products darzalex percent free cash flow deployed imbruvica stelara last years returned crohns disease shareholders form dividends anticipated regulatory approval two share repurchases new immunology products guselkumab three sirukumab greater business strong record total shareholder billion sales potential sectors returns result approach well managing long term relentless continue vigorously positioned drive innovation disciplined portfolio defend patents remicade meet management capital allocation remaining competitive atrisk changing strategy regularly biosimilar entries given products long needs discussed part ongoing strategic track record efficacy safety patients planning board directors consumers confident robust driving strong consistent pharmaceutical pipeline continue sustainable results working toward goal filing new health care landscape continues products least evolve three business sectors billion potential sales well filing wellpositioned meet changing needs additional line extensions patients consumers terms million financial performance expect potential sales business segment grow contribute sales income growth addition january announced definitive agreement acquire actelion pharmaceuticals ltd approximately billion pharmaceuticals business transaction expected accelerate priority drive continued growth near longterm revenue delivering nearterm pipeline earnings growth rates immediately focusing therapeutic accretive johnson johnsons adjusted areas high unmet medical need earnings per share acquisition would robust innovation engine strong expand complement existing commercial capabilities janssen portfolio differentiated iv chairmans lettermarket medicines pulmonary arterial opportunities large growing markets hypertension reinforces janssens significant unmet needs already robust latestage pipeline transaction subject satisfaction goal return market closing conditions expected close growth second half year end second quarter plan drive growth doubling number new consumer products least major consumer segment nearterm launches planned priority enhance leadership accelerating impact strategic priority categories continue improve acquisitions made profitability benchmark levels focusing incorporating suite holistic insights critical geographies iconic driven capabilities help health systems unique megabrands navigate valuebased care perspective careadvantage orthopaedic episode plans consumer growth health ofcare partnerships include wellness continuing progress restructuring needs wants continuing grow faster initiative hospital medical device hopes market gaining market share across businesses track achieve fears mega brands savings million billion people whose bringing innovation market majority expected realized lives touch launching key sciencebased new end around products responsibility world every accelerating growth recent worlds largest broadly day acquisitions beauty franchise including vogue international ogx based health care company proganix hair care brands unique perspective health wellness needs wants hopes fears continuing utilize supply chain operational efficiencies ensure people whose lives touch around operating margins benchmark world every day levels continue providing leadership medical devices health wellness issues nearterm priority medical devices understand better anyone else accelerate growth innovation continue reporting social portfolio management new business environmental performance business models driving growth priority citizenship sustainability platforms sustaining leadership report available wwwjnjcomcaring core platforms implementing novel commercial models seeking expansion september addition chairmans letter vcitizenship sustainability goals health care system address important announced comprehensive un issue us health care costs sustainable development goals sdg commitment focused five key areas continue defend interests uniquely positioned stakeholders defined create sustainable scalable impact credo doctors nurses patients global disease challenges essential mothers fathers others use surgery womens childrens health products employees suppliers health workforce environmental communities live health sdg vision work also continue provide galvanizing partners mobilizing positive economic impact wherever employees engaging communities business pay fair share taxes profoundly improve course deliver fair return shareholders human health putting people first also industry leader keeping whether humancentered insight patient consumer center drives innovation breakthrough everything last years product advocacy access health committed taken unprecedented steps care humanitarian work treating always putting like creating johnson johnson worlds debilitating people first bioethics committee industrys first diseases committed always compassionate use advisory committee putting people first collaborating develop massive real world data sets observational health also true support data sciences informatics ohdsi employees around developing industryleading clinical trial world compelling strategies data transparency yale open strong results would possible data access yoda project without talented diverse dedicated employees commitment first quarter also passion helped johnson johnson pleased release inaugural janssen named top industry business us transparency report publications among disclosing information admired respected innovative business practices including best places work year year related pricing report builds history responsible pricing practices ensure success ongoing efforts provide believe employers opportunity transparency operate responsibility well incentive disclosures one way ensure employees healthy continuing work others engaged goal beyond vi chairmans letterto lead example cultivating worlds resilience one way achieve healthiest workforce practice gratitude would like say grateful number programs place chairman chief executive officer help us achieve goal across many johnson johnson grateful facets employees lives passion commitment unique programs encourage healthy eating contributions movement resilience ensuring employees around world grateful financial health employees billions health care workers competitive compensation programs parents consumers place health wellness benefits recognition trust products every day finally programs longterm incentives robust grateful board directors retirement plans including defined shareholders entrusting benefit pension plan us well great responsibility leading supporting healthy families amazing company thank programs new parental leave support policy fertility benefits global breast milk shipping benefits credo inspiration strength broad base across human feel right thing health care commitment also believe programs delivering strong consistent longterm help us achieve goals attracting growth incredibly confident developing retaining best talent continued success johnson johnson deliver best outcomes positioning us deliver another years strong growth sincerely shareholder returns confident future johnson johnson alex gorsky one teachings wellness chairman chief executive officer business importance mindfulness johnson johnson nongaap measure free cash flow defined operating cash flow less capital spending billion billion billion nongaap measure excludes intangible amortization expense special items note regarding forwardlooking statements letter contains forwardlooking statements relating among things future operating financial performance product development market position business strategy reader cautioned rely statements based current expectations future events important information statements including risks uncertainties factors could cause actual results vary materially assumptions expectations projections expressed forwardlooking statements reader review enclosed annual report fiscal year ended january including sections captioned cautionary note regarding forwardlooking statements item risk factors johnson johnson undertake update forwardlooking statement result new information future events developments chairmans letter viiunited states securities exchange commission washington dc annual report pursuant section securities exchange act forthefiscalyearendedjanuary commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices zipcode registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass nameofeachexchangeonwhichregistered commonstockparvalue newyorkstockexchange notesduenovember newyorkstockexchange notesduejanuary newyorkstockexchange notesduemay newyorkstockexchange notesduenovember newyorkstockexchange notesduenovember newyorkstockexchange notesduemay newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondofthe exchangeact yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordofthe exchangeactduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuch reportsandhasbeensubjecttosuchfilingrequirementsforthepastdays yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyandpostedonitscorporatewebsiteifany everyinteractivedatafilerequiredtobesubmittedandpostedpursuanttoruleofregulationstduringthe precedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtosubmitandpostsuch files yes indicatebycheckmarkifdisclosureofdelinquentfilerspursuanttoitemofregulationskisnotcontainedherein andwillnotbecontainedtothebestofregistrantsknowledgeindefinitiveproxyorinformationstatements incorporatedbyreferenceinpartiiiofthisformkoranyamendmenttothisformk indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfileror asmallerreportingcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilerandsmallerreporting companyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany donotcheckifasmallerreportingcompany indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhich thecommonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscal quarterwasapproximatelybillion onfebruarythereweresharesofcommonstockoutstanding documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfiled withindaysafterthecloseoftheregistrantsfiscalyeartheproxystatementare incorporatedbyreferencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterials patents trademarks seasonality competition researchanddevelopment environment regulation availableinformation riskfactors b unresolvedstaffcomments properties legalproceedings minesafetydisclosures executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecurities selectedfinancialdata managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures b otherinformation partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matters certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservices partiv exhibitsandfinancialstatementschedules formksummary signatures exhibitindex cautionary note regarding forwardlooking statements thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooking statementswithinthemeaningofthesafeharborprovisionsoftheusprivatesecuritieslitigationreformactof managementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimetotime makeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsandreflect managementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatementsmaybe identifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsofsimilar meaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsthecompanysstrategyforgrowthproduct developmentregulatoryapprovalsmarketpositionandexpenditures becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevents theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesobtaining regulatoryapprovalshealthplancoverageandcustomeraccessandinitialandcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheusandotherimportantmarkets theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand resultingrevenueandmarketsharelosses increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductspotentiallyresultinginlossofmarketexclusivityandrapiddeclinein salesfortherelevantproduct competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreements forproductsandtechnologies competitiononthebasisofcosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages andfutureroyalties risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheusfoodanddrugadministrationorinternational counterpartsdecliningsalesandreputationaldamage impactofsignificantlitigationorgovernmentactionadversetothecompanyincludingproductliabilityclaims increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimited todebarmentfromgovernmentbusiness failuretomeetcomplianceobligationsinthemcneilppcincconsentdecreeorthecorporateintegrityagreements ofthejohnsonjohnsonpharmaceuticalaffiliatesoranyothercomplianceagreementswithgovernmentsor governmentagencieswhichcouldresultinsignificantsanctions potentialchangestoapplicablelawsandregulationsaffectingusandinternationaloperationsincludingrelatingto approvalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccesstoand reimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofrawmaterials johnsonjohnsonannualreport changesintaxlawsandregulationsincreasingauditscrutinybytaxauthoritiesaroundtheworldandexposuresto additionaltaxliabilitiespotentiallyinexcessofreservesand issuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandthesecuritiesand exchangecommission risksrelatedtothecompanysstrategicinitiativesandhealthcaremarkettrends pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareproviderstrendstowardmanagedcareandtheshifttowardgovernmentsincreasinglybecomingthe primarypayersofhealthcareexpenses restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraints challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanyincludingtheplannedacquisitionofactelionltdmaynotberealizedormaytakelongerto realizethanexpected thepotentialthattheexpectedbenefitsandopportunitiesrelatedtotheplannedrestructuringactionsinthemedical devicesegmentmaynotberealizedormaytakelongertorealizethanexpectedincludingduetoanyrequired consultationproceduresrelatingtorestructuringofworkforceand marketconditionsandthepossibilitythatthecompanyssharerepurchaseprogrammaybedelayedsuspendedor discontinued risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargins potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheusukandothercountries includinganyincreasedtraderestrictionsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal systems changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproducts andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservices withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheusandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarkets risksrelatedtosupplychainandoperations difficultiesanddelaysinmanufacturinginternallyorwithinthesupplychainthatmayleadtovoluntaryorinvoluntary businessinterruptionsorshutdownsproductshortageswithdrawalsorsuspensionsofproductsfromthemarketand potentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsandthoseofthecompanysvendors couldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsandregulatory actionand relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompanys products investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopments johnsonjohnsonannualreportpart item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedin theresearchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnson johnsonisaholdingcompanywhichhasmorethanoperatingcompaniesconductingbusinessinvirtuallyall countriesoftheworldthecompanysprimaryfocusisproductsrelatedtohumanhealthandwellbeingjohnson johnsonwasincorporatedinthestateofnewjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerpharmaceuticalandmedicaldeviceswithinthestrategicparameters providedbythecommitteeseniormanagementgroupsatusandinternationaloperatingcompaniesareeach responsiblefortheirownstrategicplansandthedaytodayoperationsofthosecompanieseachsubsidiarywithinthe businesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthecountrywherelocated segments business thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesadditional informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments andoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsandfinancial conditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotestoconsolidated financialstatementsincludedinitemofthisreport consumer theconsumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautypreviouslyreferredto asskincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsbabycareincludesthe johnsonslineofproductsoralcareincludesthelisterineproductlinemajorbrandsinbeautyincludethe aveenocleancleardabaojohnsonsadultlepetitemarseillaisneutrogenaroc andogxproductlinesoverthecountermedicinesincludethebroadfamilyoftylenolacetaminophenproducts sudafedcoldfluandallergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofen productsandthepepcidlineofacidrefluxproductsmajorbrandsinwomenshealthoutsideofnorthamericaare stayfreeandcarefreesanitarypadsandobtamponbrandswoundcarebrandsincludethebandaid brandadhesivebandagesandneosporinfirstaidproductlinestheseproductsaremarketedtothegeneralpublic andsoldbothtoretailoutletsanddistributorsthroughouttheworld pharmaceutical thepharmaceuticalsegmentisfocusedonfivetherapeuticareasimmunologyegrheumatoidarthritisinflammatory boweldiseaseandpsoriasisinfectiousdiseasesandvaccineseghivhepatitisrespiratoryinfectionsand tuberculosisneuroscienceegalzheimersdiseasemooddisordersandschizophreniaoncologyegprostate cancerhematologicmalignanciesandlungcancerandcardiovascularandmetabolicdiseasesegthrombosisand diabetesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealthcare professionalsforprescriptionusekeyproductsinthepharmaceuticalsegmentincluderemicadeinfliximaba treatmentforanumberofimmunemediatedinflammatorydiseasessimponigolimumabasubcutaneoustreatment foradultswithmoderatetosevererheumatoidarthritisactivepsoriaticarthritisactiveankylosingspondylitisand moderatelyactivetoseverelyactiveulcerativecolitissimponiariagolimumabanintravenoustreatmentforadults withmoderatetosevererheumatoidarthritisstelaraustekinumabatreatmentforadultswithmoderatetosevere plaquepsoriasisandactivepsoriaticarthritisandforadultswithmoderatelytoseverelyactivecrohnsdisease prezistadarunaviredurantrilpivirineandprezcobixrezolstadarunavircobicistatantiretroviral medicinesforthetreatmentofhumanimmunodeficiencyvirushivincombinationwithotherantiretroviralproducts johnsonjohnsonannualreport concertamethylphenidatehclextendedreleasetabletsciiatreatmentforattentiondeficithyperactivitydisorder invegapaliperidoneextendedreleasetabletsforthetreatmentofschizophreniaandschizoaffectivedisorder invegasustennaxeplionpaliperidonepalmitateforthetreatmentofschizophreniaandschizoaffective disorderinadultsinvegatrinzatrevictapaliperidonepalmitateforthetreatmentofschizophreniainpatients aftertheyhavebeenadequatelytreatedwithinvegasustennaforatleastfourmonthsrisperdalconsta risperidonelongactinginjectionforthetreatmentofschizophreniaandthemaintenancetreatmentofbipolardisorder inadultsvelcadebortezomibatreatmentformultiplemyelomaandforuseincombinationwithrituximab cyclophosphamidedoxorubicinandprednisoneforthetreatmentofadultpatientswithpreviouslyuntreatedmantlecell lymphomazytigaabirateroneacetateusedincombinationwithprednisoneasatreatmentformetastaticcastration resistantprostatecancerimbruvicaibrutinibanoraloncedailytherapyapprovedforuseintreatingcertainbcell malignanciesorbloodcancersandwaldenstrmsmacroglobulinemiadarzalexdaratumumabforthetreatmentof relapsedrefractorymultiplemyelomaprocritepoetinalfasoldoutsidetheusaseprextostimulateredblood cellproductionxareltorivaroxabananoralanticoagulantforthepreventionofdeepveinthrombosisdvtwhich mayleadtopulmonaryembolismpeinpatientsundergoinghiporkneereplacementsurgerytoreducetheriskofstroke andsystemicembolisminpatientswithnonvalvularatrialfibrillationforthetreatmentandreductionofriskofrecurrenceof dvtandpeinvokanacanagliflozinforthetreatmentofadultswithtypediabetesinvokametvokanamet canagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinandmetforminhydrochlorideforthe treatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetforminhydrochlorideextendedrelease aoncedailyfixeddosecombinationtherapyofcanagliflozinandmetforminhydrochlorideextendedreleaseforthe treatmentofadultswithtypediabetesmanyofthesemedicinesweredevelopedincollaborationwithstrategicpartners orarelicensedfromothercompaniesandmaintainactivelifecycledevelopmentprograms medicaldevices themedicaldevicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgerycardiovascular diabetescareandvisioncarefieldstheseproductsaredistributedtowholesalershospitalsandretailersandused principallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinicstheyinclude orthopaedicproductsgeneralsurgerybiosurgicalendomechanicalandenergyproductselectrophysiologyproductsto treatcardiovasculardiseasesterilizationanddisinfectionproductstoreducesurgicalinfectiondiabetescareproducts suchasbloodglucosemonitoringandinsulindeliveryproductsanddisposablecontactlenses fordetailsregardingacquisitionsanddivestituresseenotetotheconsolidatedfinancialstatementsincludedin item geographic areas thebusinessofjohnsonjohnsonisconductedbymorethanoperatingcompanieslocatedincountries includingtheusinvirtuallyallcountriesthroughouttheworldtheproductsmadeandsoldintheinternationalbusiness includemanyofthosedescribedaboveundersegmentsofbusinessconsumerpharmaceuticalandmedical deviceshowevertheprincipalmarketsproductsandmethodsofdistributionintheinternationalbusinessvarywiththe countryandtheculturetheproductssoldininternationalbusinessincludethosedevelopedintheusandby subsidiariesabroad investmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivities becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties raw materials rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patents thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir productsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial johnsonjohnsonannualreportimportancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanyslargestproductremicadeinfliximabaccountedforapproximatelyofthecompanys totalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompany therearetwosetsofpatentsrelatedspecificallytoremicadethefirstsetofpatentsiscoownedbyjanssen biotechincawhollyownedsubsidiaryofjohnsonjohnsonandnyulangonemedicalcenternyujanssen biotechinchasanexclusivelicensetonyusinterestsinthepatentsthesepatentshaveexpiredinallcountriesoutside theunitedstatesintheunitedstatestheoneremainingpatentwhichexpiresinseptemberstandsrejected followingreexaminationproceedingsinstitutedbyathirdpartyintheunitedstatespatentandtrademarkofficeuspto thepatenthasalsobeenheldinvalidbythefederaldistrictcourtinthedistrictofmassachusettsthedecisionsbythe usptoandthefederaldistrictcourthavebeenappealedtotheuscourtofappealsforthefederalcircuitthe appealsarepending thesecondsetofpatentsspecificallyrelatedtoremicadewasgrantedtothekennedyinstituteofrheumatologyin europecanadaaustraliaandtheunitedstatesjanssenbiotechinchaslicensesexclusiveforhumanantitnf antibodiesandsemiexclusivefornonhumanantitnfantibodiestothesepatentswhichexpireinoutsideofthe unitedstatesandintheunitedstatescertainofthesepatentshavebeensuccessfullychallengedandinvalidated andothersareunderreviewinvariouspatentofficesaroundtheworldandarealsosubjecttolitigationincanada thecompanydoesnotexpectthatanyextensionswillbeavailablefortheabovedescribedpatentsspecificallyrelatedto remicadeinathirdpartyreceivedapprovalfromthefoodanddrugadministrationforsaleofitsinfliximab biosimilarintheunitedstatesandintroduceditsbiosimilartotheusmarketinlateforamoreextensive descriptionoflegalmattersregardingthepatentsrelatedtoremicadeseenotelegalproceedingsintellectual propertypharmaceuticalremicaderelatedcasesofthenotestoconsolidatedfinancialstatementsincludedin itemofthisreport inadditiontocompetingintheimmunologymarketwithremicadethecompanyiscurrentlymarketingstelara ustekinumabsimponigolimumabandsimponiariagolimumabnextgenerationimmunologyproductswith remainingpatentlivesofuptosevenyears trademarks thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountries wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesses seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghasbeenheavierinthefourth quarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertisingand researchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexisting productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareas ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion johnsonjohnsonannualreport research development researchactivitiesrepresentasignificantpartofthecompanysbusinessesresearchanddevelopmentexpenditures relatetotheprocessesofdiscoveringtestinganddevelopingnewproductsimprovingexistingproductsaswellas demonstratingproductefficacyandregulatorycompliancepriortolaunchthecompanyremainscommittedtoinvesting inresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproductsworldwidecostsofresearch anddevelopmentactivitiesamountedtobillionbillionandbillionforfiscalyearsand respectivelyresearchfacilitiesarelocatedintheunitedstatesbelgiumbrazilcanadachinafrancegermanyindia israeljapanthenetherlandssingaporeswitzerlandandtheunitedkingdom environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieves thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsdidnotchangeduringthepastyearandisnotexpectedtohaveamaterialeffect uponitscapitalexpenditurescashflowsearningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations areconductedandthegeneraltrendistowardincreasinglystringentregulationintheusthedrugdeviceandcosmetic industrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproductsafety efficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbytheus foodanddrugadministrationthefdacontinuestoresultinincreasesintheamountsoftestinganddocumentation requiredforfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseofproductintroduction similartrendsarealsoevidentinmajormarketsoutsideoftheus thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedondrugprices andprofitsandprogramsthatencouragedoctorstowriteprescriptionsforparticulardrugsortorecommenduseor purchaseparticularmedicaldevicespayershavebecomeamorepotentforceinthemarketplaceandincreasedattention isbeingpaidtodrugandmedicaldevicepricingappropriatedrugandmedicaldeviceutilizationandthequalityandcosts ofhealthcaregenerally usgovernmentagenciescontinuetoimplementtheextensiverequirementsofthepatientprotectionandaffordablecare acttheacathesehavebothpositiveandnegativeimpactsontheushealthcareindustrywithmuchremaining uncertainastohowvariousprovisionsoftheacaandpotentialmodificationorrepealofacaprovisionswillultimately affecttheindustry theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectitto actionssuchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthe companyssubsidiariesmaydeemitadvisabletoinitiateproductrecalls inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheunited statesbygovernmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskof significantcivilandcriminalpenalties furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsthatmayaffectsourcingsupplyandpricingofmaterialsusedinthe companysproductstheseprocessesalsoaresubjecttolengthyregulatoryapprovals available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomcopiesofthecompanysquarterlyreportson formqannualreportonformkandcurrentreportsonformkfiledorfurnishedtotheussecuritiesand exchangecommissionthesecandanyamendmentstotheforegoingwillbeprovidedwithoutchargetoany shareholdersubmittingawrittenrequesttothesecretaryattheprincipalexecutiveofficesofthecompanyorbycalling allofthecompanyssecfilingsarealsoavailableonthecompanyswebsiteatwwwinvestorjnjcom seccfmassoonasreasonablypracticableafterhavingbeenelectronicallyfiledorfurnishedtothesecallsecfilings johnsonjohnsonannualreportarealsoavailableatthesecswebsiteatwwwsecgovinadditionthewrittenchartersoftheauditcommitteethe compensationbenefitscommitteethenominatingcorporategovernancecommitteetheregulatorycompliance governmentaffairscommitteeandthesciencetechnologysustainabilitycommitteeoftheboardofdirectorsandthe companysprinciplesofcorporategovernancecodeofbusinessconductforemployeescodeofbusiness conductethicsformembersoftheboardofdirectorsandexecutiveofficersandothercorporategovernance materialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbeprovidedwithoutchargeto anyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonthecompanyswebsiteisnotand willnotbedeemedapartofthisreportorincorporatedintoanyotherfilingsthecompanymakeswiththesec item risk factors thecompanyfacesanumberofuncertaintiesandrisksthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinadditiontotheotherinformationinthisreportandthecompanysotherfilingswiththesec investorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbeawarethatitisnotpossibletopredict oridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacompletediscussionofallpotentialrisksor uncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompanysbusinessresultsofoperationsor financialconditioncouldbeadverselyaffectedpotentiallyinamaterialway oneofthecompanyskeyproductsremicadeinfliximabisexperiencingbiosimilarcompetitionwhich willresultinareductioninussalesofremicade thecompanyhasexperiencedsignificantchallengestopatentscoveringitslargestproductremicadeinfliximab accountingforapproximatelyofthecompanystotalrevenuesforfiscalandcontinuestoassertcertain patentsrelatedtotheproductinaprilthefdaapprovedforsaleintheunitedstatesaninfliximabbiosimilartobe marketedbyasubsidiaryofpfizerincinoctoberthenoticeoflaunchperiodundertheusbiologicsprice competitionandinnovationactthebpciapassedandinnovemberpfizerbeganshipmentofaninfliximab biosimilartowholesalersintheunitedstatessalesofaninfliximabbiosimilarintheusmarketwillresultinareductionin ussalesofremicade globalsalesinthecompanyspharmaceuticalandmedicaldevicessegmentsmaybenegativelyimpacted byhealthcarereformsandincreasingpricingpressures salesofthecompanyspharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby thirdpartypayerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsas partofvariouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhich productswillbereimbursedintheunitedstatesincreasedpurchasingpowerofentitiesthatnegotiateonbehalfof medicaremedicaidandprivatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareproviders couldresultinfurtherpricingpressuresoutsidetheunitedstatesnumerousmajormarketsincludingtheeuandjapan havepervasivegovernmentinvolvementinfundinghealthcareandinthatregarddirectlyorindirectlyimposeprice controlslimitaccesstoorreimbursementforthecompanysproductsorreducethevalueofitsintellectualproperty protection thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpensesfinesand reputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits involvingvariousissuessuchaspatentdisputesproductliabilityandclaimsthattheirproductsalesmarketingandpricing practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthemostsignificantofthese proceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatements includedinitemofthisreportwhilethecompanybelievesithassubstantialdefensesinthesemattersitisnotfeasible topredicttheultimateoutcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificantamountsasa resultofsettlementsorjudgmentsinthesematterspotentiallyinexcessofaccrualstheresolutionoforincreasein accrualsforoneormoreofthesemattersinanyreportingperiodcouldhaveamaterialadverseeffectonthecompanys resultsofoperationsandcashflowsforthatperiodfurthermoreasaresultofcostandavailabilityfactorseffective novemberthecompanyceasedpurchasingthirdpartyproductliabilityinsurance productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand resultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbyregulatorsorconsumeradvocatesandwhetherornot basedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryactionon johnsonjohnsonannualreport thepartofthefdaoritscounterpartinothercountriesprivateclaimsandlawsuitspaymentoffinesandsettlements decliningsalesandreputationaldamagethesecircumstancescanalsoresultindamagetobrandimagebrandequity andconsumertrustinthecompanysproductsproductrecallshaveinthepastandcouldinthefutureprompt governmentinvestigationsandinspectionstheshutdownofmanufacturingfacilitiescontinuedproductshortagesand relatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivilpenaltiesandcriminalprosecution changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompanys operatingresults changesintaxlawsorregulationsincludingtaxreformproposalsintheusbelgiumandswitzerlandcouldnegatively impactthecompanyseffectivetaxrateandresultsofoperationsachangeinstatutorytaxratemayresultinthe revaluationofthecompanysdeferredtaxassetsandliabilitiesrelatedtotherelevantjurisdictionintheperiodinwhichthe newtaxlawisenactedpotentiallyresultinginamaterialexpenseorbenefitrecordedtothecompanysconsolidated statementofearningsforthatperiodforadiscussionofrisksofchangesintaxratesinothercountriesincluding belgiumpleaseseemanagementsdiscussionandanalysisofresultsofoperationsandfinancialconditionother informationeconomicandmarketfactorsinitemofthisreport thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxauditsinprogresswith manytaxauthoritiesinconnectionwiththeorganizationforeconomiccooperationanddevelopmentbaseerosionand profitshiftingbepsprojectstartingincompaniesarerequiredtodisclosemoreinformationtotaxauthoritieson operationsaroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedinothercountriesthecompany regularlyassessesthelikelyoutcomesofitstaxauditstodeterminetheappropriatenessofitstaxreserveshoweverany taxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothecompanysexpectationswhichcouldresultintax liabilitiesinexcessofreserves thecompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto thecompanysbusinesses thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsdeterminedbypatentoffices courtsandlawmakersinvariouscountriesrelatingtoitsproductsandmanufacturingprocessestheserightsareessential tothecompanysbusinessesandmateriallyimportanttothecompanysresultsofoperationspublicpolicybothwithin andoutsidetheushasbecomeincreasinglyunfavorabletowardintellectualpropertyrightsthecompanycannotbe certainthatitwillobtainadequatepatentprotectionfornewproductsandtechnologiesintheusandotherimportant marketsorthatsuchprotectionsoncegrantedwilllastaslongasoriginallyanticipated competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryrights throughlitigationinterferencesoppositionsandotherproceedingstheseproceedingsabsorbresourcesandcanbe protractedaswellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthird partiescouldresultintheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand salesoftheproductsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheunitedstatesmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththefdathebpciaenactedinwhichcreatedanewregulatorypathwayfortheapprovalby thefdaofbiosimilaralternativestoinnovatordevelopedbiologicalproductsalsocreatedmechanismsforbiosimilar applicantstochallengethepatentsontheinnovatorbiologicstheinterpartesreviewiprprocesswiththeuspto createdundertheamericainventsactisalsobeingusedbycompetitorstochallengepatentsheldbythe companyssubsidiariesforexampleakeypatentforzytigaiscurrentlysubjecttopatentlitigationandseveralipr proceedingsbroughtbygenericcompaniesseekingtoinvalidatethepatent intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch despitependingpatentinfringementlitigationbythegenericorbiosimilarfirmofitsproductthecompanycanlosea majorportionofrevenuesforthereferencedproductinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthe companyspatentsandotherintellectualpropertyrightsaredescribedinnotelegalproceedingsintellectual propertyofthenotestotheconsolidatedfinancialstatementsincludedinitemofthisreport johnsonjohnsonannualreportthecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearnings thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologies mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitors developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofuscouldnegativelyimpactsalesofthecompanysexistingproductsas wellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproductdevelopment forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedicaldevice businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompanys consumerbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsifthe companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproducts significantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproducts technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproducts losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduced withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproducts thecompanyfacesincreasingregulatoryscrutinywhichimposessignificantcompliancecostsandexposes thecompanytogovernmentinvestigationslegalactionsandpenalties likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheunitedstatesandothercountriesinwhichtheyoperate regulatoryissuesregardingcompliancewithgoodmanufacturingpracticescgmpandcomparablequalityregulations inforeigncountriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproduct recallsproductshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthe marketingpricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsincluding underthefederalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstate unfairtradepracticesactsandconsumerprotectionlawsincreasedscrutinyofhealthcareindustrybusinesspracticesin johnsonjohnsonannualreport recentyearsbygovernmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsand prosecutionscarryriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipation ingovernmenthealthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusiness andresultsofoperationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesare describedinnotelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancial statementsincludedinitemofthisreport thecompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivityoutsidetheusareaccompaniedbycertainfinancial economicandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollars inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesthecompanyhasaccountedforoperationsinvenezuelaashighly inflationaryasthepriorthreeyearcumulativeinflationratesurpassedwhilethecompanystrivestomaintainprofit marginsintheseareasthroughcostreductionprogramsproductivityimprovementsandperiodicpriceincreasesitmight experienceoperatinglossesasaresultofcontinuedinflationinadditiontheimpactofcurrencydevaluationsincountries experiencinghighinflationratesorsignificantcurrencyexchangefluctuationscouldnegativelyimpactthecompanys operatingresults illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand profitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernits internationalbusinesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeign corruptpracticesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganything ofvaluetoforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompany obtainorretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandtherefore involvessignificantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalizing corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprograms otherlegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirements compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions potentialnationalizationorexpropriationofthecompanysforeignassetsand disruptionstomarketsduetowararmedconflictterrorismsocialupheavalsorpandemics johnsonjohnsonannualreportinterruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssales andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthesesubsidiariesoperatemanufacturingfacilitiesaswellassourcingfromhundredsof suppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipatedinterruptionsand delaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccurformanyreasons includingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputessitespecificincidentssuchas firesnaturaldisastersrawmaterialshortagespoliticalunrestandterroristattackssuchdelaysanddifficultiesin manufacturingcanresultinproductshortagesdeclinesinsalesandreputationalimpactaswellassignificantremediation andrelatedcostsassociatedwithaddressingtheshortage aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternalinformationtechnologyitsystemsandnetworksand thoseofthirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusiness plansfinancialinformationintellectualpropertyandpersonaldatatheextensiveinformationsecurityandcybersecurity threatswhichaffectcompaniesgloballyposearisktothesecurityandavailabilityoftheseitsystemsandnetworksand theconfidentialityintegrityandavailabilityofthecompanyssensitivedatathecompanycontinuallyassessesthese threatsandmakesinvestmentstoincreaseinternalprotectiondetectionandresponsecapabilitiesaswellasensurethe companysthirdpartyprovidershaverequiredcapabilitiesandcontrolstoaddressthisrisktodatethecompanyhas notexperiencedanymaterialimpacttoourbusinessoroperationsresultingfrominformationorcybersecurityattacks howeverbecauseofthefrequentlychangingattacktechniquesalongwiththeincreasedvolumeandsophisticationofthe attacksthereisthepotentialforthecompanytobeadverselyimpactedthisimpactcouldresultinreputational competitiveoperationalorotherbusinessharmaswellasfinancialcostsandregulatoryaction item b unresolved staff comments notapplicable item properties thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follows squarefeet segment inthousands consumer pharmaceutical medicaldevices worldwidetotal withintheunitedstatessevenfacilitiesareusedbytheconsumersegmentsevenbythepharmaceuticalsegmentand bythemedicaldevicessegmentoutsideoftheunitedstatesfacilitiesareusedbytheconsumersegmentby thepharmaceuticalsegmentandbythemedicaldevicessegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows squarefeet geographicarea numberoffacilities inthousands unitedstates europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal johnsonjohnsonannualreport inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworldresearchfacilitiesarealsodiscussedinitemofthisreportunderbusinessresearch anddevelopment thecompanyssubsidiariesgenerallyseektoowntheirmanufacturingfacilitiesalthoughsomeprincipallyinnonus locationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengagescontract manufacturers thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingconditionandrepairandthefacilitiesare wellutilized mcneilppcincnowjohnsonjohnsonconsumerincmcneilppccontinuestooperateunderaconsentdecree signedinwiththefdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsandrequires mcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafortwashingtonpennsylvaniaandlas piedraspuertoricotheconsentdecreethefortwashingtonfacilitywasvoluntarilyshutdowninapriland subsequentlymanyproductsweretransferredtoothermanufacturingsitesandsuccessfullyreintroducedtothemarket aftermcneilppcsuccessfullycompletedallrequirementscontainedintheconsentdecreeworkplansforthe lancasterandlaspiedrasmanufacturingsitesandcompletedthestepsrequiredforthirdpartycertificationofthefort washingtonplantathirdpartycgmpexpertsubmittedwrittencertificationstothefdaforallthreemanufacturingsites followingfdainspectionsinmcneilppcreceivednotificationsfromthefdathatallthreemanufacturingfacilities areinconformitywithapplicablelawsandregulationscommercialproductioninfortwashingtonstartedasof september undertheconsentdecreeafterreceivingnoticefromthefdaofbeingincompliancewithapplicablelawsand regulationseachofthethreefacilitiesissubjecttoafiveyearauditperiodbyathirdpartycgmpexpertthusathird partyexpertwillcontinuetoreassessthesitesatvarioustimesforatleastfiveyearsadiscussionoflegalproceedings relatedtothismattercanbefoundinnotelegalproceedingsgovernmentproceedingsmcneilconsumer healthcareofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport forinformationregardingleaseobligationsseenoterentalexpenseandleasecommitmentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreportsegmentinformationonadditionstopropertyplant andequipmentiscontainedinnotesegmentsofbusinessandgeographicareasofthenotestoconsolidated financialstatementsincludedinitemofthisreport item legal proceedings theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport inadditionjohnsonjohnsonanditssubsidiariesarefromtimetotimepartytogovernmentinvestigationsinspectionsor otherproceedingsrelatingtoenvironmentalmattersincludingtheircompliancewithapplicableenvironmentallaws item mine safety disclosures notapplicable johnsonjohnsonannualreportexecutive officers registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyincludinginformationforalexgorskyisincorporatedhereinby referencetothematerialcaptioneditemelectionofdirectorsintheproxystatement name age position dominicjcaruso memberexecutivecommitteeexecutivevicepresidentchieffinancial officera joaquinduato memberexecutivecommitteeexecutivevicepresidentworldwidechairman pharmaceuticalsb petermfasolo memberexecutivecommitteeexecutivevicepresidentchiefhuman resourcesofficerc alexgorsky chairmanboardofdirectorschairmanexecutivecommitteechiefexecutive officer jorgemesquita memberexecutivecommitteeexecutivevicepresidentworldwidechairman consumerd sandraepeterson memberexecutivecommitteeexecutivevicepresidentgroupworldwide chairmane garypruden memberexecutivecommitteeexecutivevicepresidentworldwidechairman medicaldevicesf paulusstoffels memberexecutivecommitteeexecutivevicepresidentchiefscientific officerg michaelhullmann memberexecutivecommitteeexecutivevicepresidentgeneralcounselh mrdjcarusojoinedthecompanyinwhenthecompanyacquiredcentocorincatthetimeofthatacquisitionhehadbeen seniorvicepresidentfinanceofcentocormrcarusowasnamedvicepresidentfinanceoforthomcneilpharmaceuticalinca subsidiaryofthecompanyinandvicepresidentgroupfinanceofthecompanysmedicaldevicesanddiagnosticsgroupin inmrcarusowasnamedvicepresidentofthecompanysgroupfinanceorganizationmrcarusobecameamember oftheexecutivecommitteeandvicepresidentfinanceandchieffinancialofficerininaprilhewasnamedexecutive vicepresidentchieffinancialofficer b mrjduatojoinedthecompanyinwithjanssenfarmaceuticasaspainandinbecamemanagingdirectorof janssencilagspaitalyinheledorthobiotecheuropebeforerelocatingtotheunitedstatesintoserveasvice presidentandinpresidentoforthobiotechincinhewasnamedcompanygroupchairmanorthoclinical diagnosticsandincompanygroupchairmanpharmaceuticalswhereheoversawpharmaceuticalproductlaunchesandthe majortherapeuticfranchisesincanadatheunitedstatesandlatinamericainhewasnamedworldwidechairman pharmaceuticalsresponsiblefortheglobalcommercialbusinessesofthejanssenpharmaceuticalcompaniesincludingfunctional supportfortheresearchdevelopmentorganizationsinaprilmrduatobecameamemberoftheexecutivecommitteeand wasnamedexecutivevicepresidentworldwidechairmanpharmaceuticals c drpmfasolojoinedthecompanyinasvicepresidentworldwidehumanresourcesforcordiscorporationasubsidiary ofthecompanyhewasthennamedvicepresidentglobaltalentmanagementforthecompanyheleftjohnsonjohnsonin tojoinkohlbergkravisrobertscoaschieftalentofficerdrfasoloreturnedtothecompanyinasthevice presidentglobalhumanresourcesandinhebecameamemberoftheexecutivecommitteeinaprilhewasnamed executivevicepresidentchiefhumanresourcesofficer mrjmesquitajoinedthecompanyinasworldwidechairmanconsumerpriortojoiningthecompanyheservedinvarious marketingandleadershipcapacitiesacrosslatinamericaincludingrolesinoralcareandbeautyattheproctergamble companyfromtoinaprilmrmesquitabecameamemberoftheexecutivecommitteeandwasnamedas executivevicepresidentworldwidechairmanconsumer e mssepetersonjoinedthecompanyinasgroupworldwidechairmanandamemberoftheexecutivecommitteeshe overseestheconsumerandconsumermedicaldevicebusinessesthecompanysoperatinginfrastructuresupplychain informationtechnologyglobalserviceshealthwellnessglobaldesignandhealthtechnologypriortojoiningthecompany mspetersonwaschairmanandchiefexecutiveofficerofbayercropscienceagingermanypreviouslyservingaspresidentand chiefexecutiveofficerofbayermedicalcareandpresidentofbayerhealthcareagsdiabetescaredivisionbeforejoiningbayer johnsonjohnsonannualreport inmspetersonheldanumberofleadershiprolesatmedcohealthsolutionspreviouslyknownasmerckmedcoinapril mspetersonwasnamedexecutivevicepresidentgroupworldwidechairmanofjohnsonjohnsoneffectivejune mspetersonwillassumeleadershipofthehospitalmedicaldevicebusinessinadditiontohercurrentresponsibilities f mrgprudenjoinedthecompanyinwithjanssenpharmaceuticaincandheldanumberofseniorpositionsinsales marketingandstrategicaccountmanagementinaprilhebecamepresidentofjanssenorthoincincanadainjanuary mrprudenwasappointedworldwidepresidentethiconproductsandinbecamecompanygroupchairmanethicon inhewasnamedworldwidechairmanglobalsurgerygroupandinworldwidechairmanmedicaldevicesinapril mrprudenbecameamemberoftheexecutivecommitteeandwasnamedexecutivevicepresidentworldwidechairman medicaldevicesmrprudenhasannouncedhisintentiontoretirefromthecompanyeffectivejune g drpstoffelsjoinedthecompanyinwiththeacquisitionoftibotecvirconvwherehewaschiefexecutiveofficerofvirco nvandchairmanoftibotecnvinhewasappointedcompanygroupchairmanglobalvirologyinheassumedthe roleofcompanygroupchairmanpharmaceuticalswithresponsibilityforworldwideresearchanddevelopmentforthecentral nervoussystemandinternalmedicinefranchisesdrstoffelswasappointedglobalheadresearchdevelopment pharmaceuticalsinandinbecameworldwidechairmanpharmaceuticalswithresponsibilityforthecompanys therapeuticpipelinethroughglobalresearchanddevelopmentandstrategicbusinessdevelopmentindrstoffelswasalso appointedchiefscientificofficerwithresponsibilityforenterprisewideinnovationandproductsafetyandamemberofthe executivecommitteeinaprildrstoffelswasnamedexecutivevicepresidentchiefscientificofficer h mrmhullmannjoinedthecompanyinasacorporateattorneyinthelawdepartmenthewasappointedcorporate secretaryinandservedinthatroleuntilduringthattimehealsoheldvariousmanagementpositionsinthelaw departmentinhewasnamedgeneralcounselmedicaldevicesanddiagnosticsandwasappointedvicepresidentgeneral counselandamemberoftheexecutivecommitteeininaprilmrullmannwasnamedexecutivevicepresident generalcounsel johnsonjohnsonannualreportpart ii item market registrants common equity related stockholder matters issuer purchases equity securities asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportitemmanagements discussionandanalysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesdividends andotherinformationcommonstockmarketpricesnotecommonstockstockoptionplansandstock compensationagreementsofthenotestoconsolidatedfinancialstatementsincludedinitemanditemsecurity ownershipofcertainbeneficialownersandmanagementandrelatedstockholdermattersequitycompensationplan information issuer purchases equity securities onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasestakeplace ontheopenmarketfromtimetotimebasedonmarketconditionstherepurchaseprogramhasnotimelimitandmaybe delayedorsuspendedforperiodsordiscontinuedatanytime thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunits approximatedollar purchasedaspart valueofsharesorunits totalnumber ofpublicly thatmayyetbe ofshares avgprice announcedplans purchasedundertheplans period purchased paidpershare orprograms orprograms octoberthrough october octoberthrough november novemberthrough january total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsofwhichshareswerepurchasedpursuanttotherepurchaseprogramthat waspubliclyannouncedonoctoberandofwhichshareswerepurchasedinopenmarkettransactionsaspart ofasystematicplantomeettheneedsofthecompanyscompensationprograms asofjanuaryanaggregateofshareswerepurchasedforatotalofbillionsincetheinceptionofthe repurchaseprogramannouncedonoctober asofjanuarythemaximumnumberofsharesthatmayyetbepurchasedundertheplanisbasedontheclosing priceofjohnsonjohnsoncommonstockonthenewyorkstockexchangeondecemberofpershare johnsonjohnsonannualreport item selected financial data summary operations statistical data dollarsinmillionsexcept pershareamounts salestocustomersus salestocustomers international totalsales costofproductssold sellingmarketingand administrativeexpenses researchanddevelopment expense inprocessresearchand development interestincome interestexpensenetof portioncapitalized otherincomeexpensenet restructuring earningsbeforeprovisionfor taxesonincome provisionfortaxesonincome netearnings addnetlossattributableto noncontrollinginterest netearningsattributable tojohnsonjohnson percentofsalestocustomers dilutednetearningspershare ofcommonstock percentreturnonaverage shareholdersequity percentincrease decreaseoverprevious year salestocustomers dilutednetearningspershare supplementarybalance sheetdata propertyplantand equipmentnet additionstopropertyplant andequipment totalassets longtermdebt operatingcashflow commonstock information dividendspaidpershare shareholdersequityper share marketpricepershareyear endclose averagesharesoutstanding millions basic diluted employeesthousands attributabletojohnsonjohnson amountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreportitem managements discussion analysis results operations financial condition organization business segments descriptionofthecompanyandbusinesssegments johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautypreviouslyreferredtoas skincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedto thegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentis focusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscienceoncologyandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgerycardiovasculardiabetescareandvisioncarefieldswhicharedistributedtowholesalershospitals andretailersandusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsand clinics theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerpharmaceuticalandmedicaldevicesbusinesssegments inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion managementsobjectives thecompanymanageswithinastrategicframeworkwithourcredoasthefoundationthecompanybelievesthatour strategicoperatingprinciplesbeingbroadlybasedinhumanhealthcaremanagingthebusinessforthelongtermhaving adecentralizedmanagementapproachandbeingcommittedtoourpeopleandvaluesarecrucialtosuccessfullymeeting thedemandsoftherapidlyevolvingmarketsinwhichwecompetetothisendmanagementisfocusedonourlongterm strategicgrowthdriverscreatingvaluethroughinnovationexpandingourglobalreachwithalocalfocusexcellencein executionandleadingwithpurpose thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionorofsaleswasinvestedinresearchanddevelopmentreflecting managementscommitmenttodeliveringnewanddifferentiatedproductsandservicestomeetevolvinghealthcareneeds andsustainthecompanyslongtermgrowth ourdiversebusinesseswithmorethanoperatingcompanieslocatedincountriesarethekeydriversofthe companyssuccessmaintainingthecompanysdecentralizedmanagementapproachwhileatthesametimeleveraging theextensiveresourcesoftheenterprisepositionsthecompanywelltoinnovateexecutestrategicplansandreach marketsgloballyaswellasaddresstheneedsandchallengesofthelocalmarkets inordertoremainaleaderinhealthcarethecompanystrivestomaintainapurposedrivenorganizationandiscommitted todevelopingglobalbusinessleaderswhocanachievethesegrowthobjectivesbusinessesaremanagedforthelong terminordertosustainmarketleadershippositionsandenablegrowthwhichprovidesanenduringsourceofvaluetoour shareholders johnsonjohnsonannualreport ourcredounifiesalljohnsonjohnsonemployeesinachievingtheseobjectivesandprovidesacommonsetofvalues thatserveasthefoundationofthecompanysresponsibilitiestopatientsconsumersandhealthcareprofessionals employeescommunitiesandshareholdersthecompanybelievesthatthesefoundationalvaluesitsstrategicframework andlongtermgrowthdriversalongwithitsoverallmissionofimprovingthequalityoflifeforpeoplearoundtheworldwill enablejohnsonjohnsontocontinuetobealeaderinthehealthcareindustry results operations analysisofconsolidatedsales inworldwidesalesincreasedtobillioncomparedtoadecreaseofinandanincreaseof inthesesaleschangesconsistedofthefollowing salesincreasedecreasedueto volume price currency total inacquisitionsanddivestitureshadanegativeimpactofontheworldwideoperationalsalesgrowthand competitiveproductstothecompanyshepatitiscproductsolysiosovriadsimeprevirandincivo telaprevirhadanegativeimpactofontheworldwideoperationalsalesgrowthoperationsinvenezuelanegatively impactedtheworldwideoperationalsalesgrowth intheintroductionofcompetitiveproductstothecompanyshepatitiscproductsolysiosovriad simeprevirandincivotelaprevirhadanegativeimpactofontheworldwideoperationalsalesgrowthin theimpactofacquisitionsanddivestituresontheworldwideoperationalsalesgrowthwasnegative insalesofthecompanyshepatitiscproductsolysiosovriadsimeprevirandincivotelaprevirhad apositiveimpactofandthedivestitureoftheorthoclinicaldiagnosticsbusinesshadanegativeimpactofon theworldwideoperationalgrowth salesbyuscompanieswerebillioninbillioninandbillioninthisrepresents increasesofininandinsalesbyinternationalcompanieswerebillionin billioninandbillioninthisrepresentsdecreasesofinandinandan increaseofin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively salesbycompaniesineuropeexperiencedadeclineofascomparedtotheprioryearincludingoperationalgrowth ofoffsetbyanegativecurrencyimpactofsalesbycompaniesinthewesternhemisphereexcludingthe usexperiencedadeclineofascomparedtotheprioryearincludingoperationalgrowthofoffsetbya negativecurrencyimpactofsalesbycompaniesintheasiapacificafricaregionachievedgrowthofas comparedtotheprioryearincludingoperationalgrowthofandapositivecurrencyimpactof thesalesgrowthpercentageascomparedtotheprioryearwasnegativelyimpactedbyapproximatelyfrom additionalshippingdaysinseenotetotheconsolidatedfinancialstatementsforannualclosingdatedetails whiletheadditionalweekinaddedafewdaystosalesitalsoaddedafullweeksworthofoperatingcosts thereforethenetearningsimpactwasnegligible inthecompanyhadtwowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinandthecompanyhadonewholesalerdistributing productsforallthreesegmentsthatrepresentedapproximatelyandrespectivelyofthetotalconsolidated revenues johnsonjohnsonannualreportanalysis sales business segments consumersegment consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactofintheimpactofacquisitionsanddivestituresontheconsumersegment operationalsalesgrowthwasnegativeintheconsumersegmentoperationalsalesgrowthwasnegatively impactedbyoperationsinvenezuelaandnegativelyimpactedbyduetoadditionalshippingdaysin majorconsumerfranchisesales change dollarsinmillions vs vs otc beauty babycare oralcare womenshealth woundcareother totalconsumersales prioryearamountshavebeenreclassifiedtoconformtocurrentyearproductdisclosure formerlyskincare theoverthecounterotcfranchisesalesofbillionincreasedascomparedtotheprioryearwhichincluded operationalgrowthandanegativecurrencyimpactofoperationalgrowthwasprimarilydrivenbyanalgesics antismokingaidsanddigestivehealthproducts thebeautyfranchisesalesofbillionincreasedascomparedtotheprioryearwhichincludedoperational growthandanegativecurrencyimpactofoperationalgrowthwasprimarilyduetosalesfromtherecent acquisitionsofvogueinternationalllcwhichcontributedapproximatelyandneostratacompanyincaswellas salesgrowthofneutrogenaaveenoadultproductsanddabaoproducts thebabycarefranchisesaleswerebillioninadecreaseofcomparedtotheprioryearprimarilydueto competitivepressurepartiallyoffsetbysalesgrowthofaveenobabyproducts theoralcarefranchisesaleswerebillioninadecreaseofascomparedtotheprioryearwhich includedoperationalgrowthandanegativecurrencyimpactofoperationalgrowthwasdrivenbyincreased salesoflisterineproductsattributabletonewproductlaunchesandsuccessfulmarketingcampaigns thewomenshealthfranchisesaleswerebillioninadecreaseofascomparedtotheprioryear primarilyduetooperationsinvenezuelaandtheusdivestitureoftucks thewoundcareotherfranchisesaleswerebillioninadecreaseoffromprimarilyduetothe splendadivestiture consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactofindivestitureshadanegativeimpactofontheworldwideconsumer segmentoperationalgrowth johnsonjohnsonannualreport pharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofpartiallyoffsetbyanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthpartiallyoffsetbya negativecurrencyimpactofinacquisitionsdivestituresandcompetitiveproductstothecompanyshepatitis cproductsolysiosovriadsimeprevirandincivotelaprevirhadanegativeimpactofonthe operationalgrowthofthepharmaceuticalsegmentinthepharmaceuticalsegmentoperationalgrowthwas negativelyimpactedbyduetoadditionalshippingdaysinthepharmaceuticalsegmentoperationalgrowthfor ascomparedtotheprioryearwasnotimpactedbyadjustmentstopreviousreserveestimatesasbothperiods includedapproximatelybillionofadjustments majorpharmaceutical therapeuticareasales change dollarsinmillions vs vs totalimmunology remicade simponisimponiaria stelara otherimmunology totalinfectiousdiseases edurantrilpivirine olysiosovriad prezistaprezcobixrezolsta otherinfectiousdiseases totalneuroscience concertamethylphenidate invegapaliperidone invegasustennaxepliontrinza risperdalconsta otherneuroscience totaloncology darzalex imbruvica velcade zytiga otheroncology cardiovascularmetabolismother xarelto invokanainvokamet procriteprex totalpharmaceuticalsales prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthan johnsonjohnsonannualreportimmunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearimmunologyproductsgrowthofincludedoperationalgrowthofandanegativecurrencyimpactof thestronggrowthofremicadeinfliximabstelaraustekinumabandsimponisimponiaria golimumabwasprimarilydrivenbyimmunologymarketgrowthandincreasedpenetrationforbothstelara ustekinumabandsimponisimponiariagolimumab thepatentsforremicadeinfliximabincertaincountriesineuropeexpiredinfebruarybiosimilarversionsof remicadehavebeenintroducedincertainmarketsoutsidetheunitedstatesresultinginareductioninsalesof remicadeinthosemarketsadditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninremicade salesinmarketsoutsidetheunitedstatestheintroductionofabiosimilarversionofremicadeintheunitedstatesis subjecttoenforcementofpatentrightsapprovalbytheusfoodanddrugadministrationfdaandcompliancewith thedaynoticeprovisionsofthebiologicspricecompetitionandinnovationactthebpciainaprilthefda approvedforsaleintheunitedstatesaninfliximabbiosimilartobemarketedbyasubsidiaryofpfizerincinoctober theperiodfornoticeoflaunchunderthebpciapassedandpfizerincbeganshipmentofaninfliximabbiosimilarto wholesalersintheunitedstatesinlatenovembersalesofaninfliximabbiosimilarintheusmarketwillresultina reductioninussalesofremicadethecompanycontinuestoassertremicaderelatedpatentrightssee notetotheconsolidatedfinancialstatementsforadescriptionoflegalmattersregardingtheremicadepatents infectiousdiseaseproductssaleswerebillionadeclineoffromwhichincludedanoperational decreaseofandanegativecurrencyimpactofcompetitiveproductstothecompanyshepatitisc productsolysiosovriadsimeprevirandincivotelaprevirhadasignificantnegativeimpactonsalesthe declineofhepatitiscsaleswaspartiallyoffsetbysalesgrowthofedurantrilpivirineandprezcobixdarunavir cobicistat neuroscienceproductssaleswerebillionadecreaseoffromwhichincludedanoperationaldecreaseof andanegativecurrencyimpactofstrongsalesofinvegasustennaxepliontrinzapaliperidone palmitatewereoffsetbylowersalesofinvegapaliperidoneduetogenericcompetitionrisperdalconsta risperidoneandtheimpactofdivestituressalesgrowthofconcertamethylphenidatewasprimarilyduetoa therapeuticequivalencereclassificationofgenericcompetitors oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearoncologyproductsgrowthofincludedoperationalgrowthofandanegativecurrencyimpactof contributorstothegrowthofoncologyproductswerestrongsalesofimbruvicaibrutinibanddarzalex daratumumabduetopatientuptakeadditionalcountrylaunchesandadditionalindicationsforimbruvicageneric competitionnegativelyimpactedthesalesgrowthofvelcadebortezomibsalesgrowthofzytigaabiraterone acetateintheasiapacificregionprimarilyduetothelaunchinchinaearlierthisyearwaspartiallyoffsetbylowersales ineuropeduetocompetition cardiovascularmetabolismotherproductssaleswerebillionadeclineoffromwhichincludedan operationalincreaseofandanegativecurrencyimpactofcontributorstothegrowthwerestrongsalesof xareltorivaroxabanduetomarketsharegrowthandinvokanainvokametcanagliflozinduetomarket growthandcontinueduptakeintheeuropeanunionandcanadasalesofhormonalcontraceptiveswerenegatively impactedbygenericcompetitionandahigheradjustmenttopreviousreserveestimatesinascomparedto whichnegativelyimpactedcardiovascularmetabolismotherbyapproximately johnsonjohnsonannualreport duringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollows productnamechemical us eu us eu name indication approv approv filing filing darzalexdaratumumab incombinationwithlenalidomideanddexamethasoneor bortezomibanddexamethasoneforthetreatmentofpatientswith multiplemyelomawhohavereceivedatleastonepriortherapy forthetreatmentofdoublerefractorymultiplemyeloma darunavirstr singletabletregimenforhivintreatmentnaivepatientsand treatmentexperiencedpatients guselkumab treatmentofadultslivingwithmoderatetosevereplaque psoriasis imbruvicaibrutinib additionalindicationforfirstlinetreatmentofchroniclymphocytic leukemia expandedlabeltoincludeoverallsurvivalandcombinationdatain chroniclymphocyticleukemiasmalllymphocyticlymphomacll sll expandedlabeltoincludetreatmentforpatientswithrelapsedor refractorychroniclymphocyticleukemiacllorsmall lymphocyticlymphomaincombinationwithbendamustineand rituximab invokametcanagliflozin initialtherapyfdcwithmetforminimmediaterelease invokametxrcanagliflozin aoncedailytherapycombiningfixeddosesofcanagliflozinand metforminhydrochlorideextendedreleaseforthetreatmentof adultswithtypediabetes simponigolimumab treatmentofpolyarticularjuvenileidiopathicarthritis simponiariagolimumab treatmentofadultslivingwithactivepsoriaticarthritisandthe treatmentofadultslivingwithactiveankylosingspondylitis sirukumab treatmentofrheumatoidarthritis stelaraustekinumab treatmentofadultswithmoderatelytoseverelyactivecrohns disease treatmentofadolescentstoyearsofagewithmoderate tosevereplaquepsoriasis trevictapaliperidone maintenancetreatmentofschizophreniainadultpatients palmitateamonthlyinjection pharmaceuticalsegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthofoffsetbyanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbyanegative currencyimpactofthepharmaceuticalsegmentoperationalgrowthwasnegativelyimpactedbyduetothe introductionofcompetitiveproductstothecompanyshepatitiscproductsolysiosovriadsimeprevirand incivotelaprevirandpositivelyimpactedbyduetoanadjustmenttopreviousreserveestimatesincluding managedmedicaidrebatesprimarilyinthecardiovascularmetabolismothertherapeuticareaindivestitureshada negativeimpactofontheworldwidepharmaceuticalsegmentoperationalgrowth medicaldevicessegment themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationalincreaseofandanegativecurrencyimpactofussaleswerebillionanincreaseof ascomparedtotheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprioryear withanoperationalincreaseofandanegativecurrencyimpactofinacquisitionsanddivestitureshada negativeimpactofontheworldwideoperationalgrowthofthemedicaldevicessegmentascomparedtoin themedicaldevicessegmentoperationalgrowthwasnegativelyimpactedbyduetoadditionalshippingdays johnsonjohnsonannualreportmajormedicaldevicesfranchisesales change dollarsinmillions vs vs orthopaedics hips knees trauma spineother surgery advanced general specialty visioncare cardiovascular diabetescare diagnostics totalmedicaldevicessales onjunethecompanydivestedtheorthoclinicaldiagnosticsbusinessthediagnosticsfranchise theorthopaedicsfranchisesaleswerebillioninanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofsalesgrowthwasprimarilydrivenbymarketgrowthussalesof thetraumatfnanailingsystemworldwidesalesofthehipprimarystemplatformandtheattunekneesystem growthwasnegativelyimpactedbycontinuedpricingpressures thesurgeryfranchisesaleswerebillioninanincreaseoffromwhichincludedoperationalgrowth ofandanegativecurrencyimpactofoperationalgrowthinadvancedsurgerywasdrivenbyendocutter energyandbiosurgeryproductsprimarilyattributabletomarketgrowthincreasedpenetrationincertainmarketsandnew productlaunchestheacquisitionofneuwavemedicalincalsocontributedtogrowththeoperationaldeclinein generalsurgerywasduetolowersalesofwomenshealthandurologyproductsandpricingpressurespartiallyoffsetby growthofsuturestheoperationaldeclineinspecialtysurgerywasprimarilyduetolowersalesofacclarentproductsand advancedsterilizationproductsoutsidetheusdivestituresandcompetitivepressuresinsterilmedpartiallyoffsetby growthofmentorproductsoutsidetheus thevisioncarefranchiseachievedsalesofbillioninanincreaseoffromwhichincluded operationalgrowthofandapositivecurrencyimpactofgrowthinallthemajorregionswasprimarilydrivenby newproductlaunches thecardiovascularfranchisesaleswerebillionadecreaseoffromwhichrepresentedanoperational declineofstrongoperationalgrowthintheelectrophysiologybusinessdrivenbymarketgrowthsharegrowthand newproductlauncheswasmorethanoffsetbytheimpactofdivestingthecordisbusinessthecompanycompletedthe divestitureofthecordisbusinesstocardinalhealthonoctoberforadditionaldetailsseenotetothe consolidatedfinancialstatements thediabetescarefranchisesaleswerebillionadecreaseoffromwhichrepresentedanoperational declineofandanegativecurrencyimpactoftheoperationaldeclinewasprimarilyduetopricedeclinesand competitivepressuresonjanuarysubsequenttoyearendthecompanyannounceditisengagingina processtoevaluatepotentialstrategicoptionsforthediabetescarefranchise themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationaldeclineofandanegativecurrencyimpactofussaleswerebillionadecreaseofas comparedtotheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprioryearwith anoperationaldecreaseofandanegativecurrencyimpactofthedivestituresoftheorthoclinical diagnosticsandthecordisbusinesseshadanegativeimpactofandrespectivelyontheworldwide operationalgrowthofthemedicaldevicessegmentascomparedto johnsonjohnsonannualreport analysis consolidated earnings provision taxes income consolidatedearningsbeforeprovisionfortaxesonincomeincreasedtobillioninascomparedto billioninanincreaseoftheincreasewasprimarilyattributabletohighersalesvolumefavorablemixin thebusinessandlowersellingmarketingandadministrativecoststhiswaspartiallyoffsetbyhighernetlitigationexpense ofbillionandahigherrestructuringchargeofbillionascomparedtoadditionallythefiscalyear includedhighergainsonthesaleofassetsbusinessesascomparedtothefiscalyearofincludedgainsof billionfromthedivestituresofthecontrolledsubstancerawmaterialandapibusinesscertainanestheticproductsin europeandcertainnonstrategicconsumerbrandsversusgainsofbillionrecordedinprimarilyfromthe divestitureofthecordisbusinesstheusdivestitureofnucyntaandthesplendabrandthiswaspartiallyoffset byabillionintangibleassetwritedownrelatedtoacclarentincludedin consolidatedearningsbeforeprovisionfortaxesonincomedecreasedtobillioninascomparedto billioninadecreaseofthedecreasewasprimarilyattributabletosignificantlylowersalesofolysio sovriadsimeprevirnegativecurrencyimpactsarestructuringchargeofbillionandhigherintangibleasset writedownsofbillioninascomparedtothedecreasewaspartiallyoffsetbylowernetlitigation expenseofbillionlowersynthesintegrationcostsofbillionapositiveadjustmentofbilliontoprevious reserveestimatesincludingmanagedmedicaidrebatesandhighergainsofbillionfromdivestituresascomparedto theprioryearthefiscalyearincludedhighergainsofbillionprimarilyfromthedivestituresofthecordis businessthesplendabrandandtheusdivestitureofnucyntaversusthegainsrecordedinfromthe divestituresoftheorthoclinicaldiagnosticsbusinessandthekybrandadditionallyincludedanadditionalyear ofthebrandedprescriptiondrugfeeofbillion asapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomeinwasversusin costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselling marketingandadministrativeexpensesasapercenttosaleswereasfollows ofsales costofproductssold percentpointincreasedecreaseovertheprioryear sellingmarketingandadministrativeexpenses percentpointincreasedecreaseovertheprioryear incostofproductssoldasapercenttosalesdecreasedtofromascomparedtothesameperioda yearagofavorablemixinthebusinessandcostimprovementprogramswaspartiallyoffsetbytheunfavorableimpactof transactionalcurrencyintangibleassetamortizationexpenseofbillionwasincludedincostofproductssoldfor andtherewasadecreaseinthepercenttosalesofsellingmarketingandadministrativeexpensesin comparedtotheprioryearprimarilyduetocostmanagementinallthesegmentsandfavorablemix incostofproductssoldasapercenttosalesincreasedslightlyascomparedtotheprioryearfavorablemix betweenthesegmentswasoffsetbymillionassociatedwiththerestructuringactivityinthemedicaldevicessegment negativetransactionalcurrencyandlowersalesofolysiosovriadsimeprevirinintangibleasset amortizationexpenseincludedincostofproductssoldforandwasbillionandbillionrespectively therewasanincreaseinthepercenttosalesofsellingmarketingandadministrativeexpensesincomparedtothe prioryearprimarilyduetoincrementalinvestmentspendinginallthesegmentsandtheimpactfromlowersalesof olysiosovriadsimeprevirpartiallyoffsetbyfavorablemixandtheinclusionofanadditionalyearofthebranded prescriptiondrugfeeofbillionin johnsonjohnsonannualreportresearchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales amount ofsales consumer pharmaceutical medicaldevices totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year asapercenttosegmentsales researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsandmilestonesimprovingexisting productsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompanyremains committedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproductsin worldwidecostsofresearchanddevelopmentactivitiesincreasedbycomparedtobutdecreasedasa percentofsalesthedecreaseasapercentofsaleswasattributabletohigheroverallsalesinthepharmaceutical segmenttheincreaseddollarspendinthepharmaceuticalsegmentwasforinvestmentspendingtoadvancethepipeline inworldwidecostsofresearchanddevelopmentactivitiesincreasedbycomparedtotheincreaseasa percenttosaleswasattributabletoincreasedinvestmentspendingprimarilyinthepharmaceuticalsegmentloweroverall salesandbusinessmix inprocessresearchanddevelopmentiprdinthecompanyrecordedaniprdchargeofmillion forthediscontinuationofadevelopmentprogramrelatedtocrucellinthecompanyrecordedaniprdchargeof billionprimarilyforthediscontinuationofcertaindevelopmentprojectsrelatedtocovageninthecompany recordedaniprdchargeofbillionfortheimpairmentofvariousiprdprojectsrelatedtorespivertcrucell mentorandsynthesforthedelayordiscontinuationofcertaindevelopmentprojects otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnson innovationjjdcincjjdcgainsandlossesondivestiturestransactionalcurrencygainsandlossesacquisition relatedcostslitigationaccrualsandsettlementsaswellasroyaltyincomethechangeinotherincomeexpensenetfor thefiscalyearwasanunfavorablechangeofbillionascomparedtotheprioryearprimarilyduetohighergains onthesaleofassetsbusinessesinthefiscalyearascomparedtothefiscalyearofincludedgainsof billionfromthedivestituresofthecontrolledsubstancerawmaterialandapibusinesscertainanestheticproductsin europeandcertainnonstrategicconsumerbrandsversusgainsofbillionrecordedinprimarilyfromthe divestitureofthecordisbusinesstheusdivestitureofnucyntaandthesplendabrandadditionallythefiscal yearofincludedhigherlitigationexpenseofbillionascomparedtothiswaspartiallyoffsetbya billionintangibleassetwritedownrelatedtoacclarentincludedinthefiscalyear thechangeinotherincomeexpensenetforthefiscalyearwasafavorablechangeofbillionascomparedto theprioryearprimarilyduetolowerlitigationexpenseofbillionlowersynthesintegrationcostsofbillionand higherjjdcportfoliogainsofbillionascomparedtotheprioryearadditionallythefiscalyearincludedhigher gainsofbillionprimarilyfromthedivestituresofthecordisbusinessthesplendabrandandtheusdivestiture ofnucyntaversusthegainsrecordedinfromthedivestituresoftheorthoclinicaldiagnosticsbusinessandthe kybrandthiswaspartiallyoffsetbyhigherintangibleassetwritedownsofbillionin interestincomeexpenseinterestincomeinincreasedbymillionascomparedtoduetoahigher averagebalanceofcashcashequivalentsandmarketablesecuritiesandhigherinterestratescashcashequivalentsand marketablesecuritiestotaledbillionattheendofandaveragedbillionascomparedtothe billionaveragecashbalancein interestexpenseinwashigherascomparedtotheaveragedebtbalancewasbillioninversus billioninthetotaldebtbalanceattheendofwasbillionascomparedtobillionattheend ofthehigherdebtbalanceofapproximatelybillionwasprimarilyduetoincreasedborrowingsinfebruaryand mayofthecompanyincreasedborrowingscapitalizingonfavorabletermsinthecapitalmarketstheproceedsof theborrowingswereusedforgeneralcorporatepurposesprimarilythestockrepurchaseprogram johnsonjohnsonannualreport interestincomeinincreasedbymillionascomparedtoduetoahigheraveragebalanceofcashcash equivalentsandmarketablesecuritiesandhigherinterestratescashcashequivalentsandmarketablesecuritiestotaled billionattheendofandaveragedbillionascomparedtothebillionaveragecashbalancein theincreaseintheyearendcashbalancewasprimarilyduetocashgeneratedfromoperatingactivities interestexpenseinincreasedslightlyascomparedtotheaveragedebtbalancewasbillionin versusbillioninthetotaldebtbalanceattheendofwasbillionascomparedtobillionat theendofthehigherdebtbalanceofapproximatelybillionwasanincreaseincommercialpaperforgeneral corporatepurposesprimarilythestockrepurchaseprogram incomebeforetaxbysegment incomebeforetaxbysegmentofbusinesswereasfollows percentof incomebeforetax segmentsales segmentsales dollarsinmillions consumer pharmaceutical medicaldevices total lessexpensesnotallocatedtosegments earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetails amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense consumersegmentintheconsumersegmentincomebeforetaxasapercenttosaleswasversus inprimarilydrivenbyfavorablesellingmarketingandadministrativeexpensesduetocostmanagementand highergrossprofitmarginsfromcostimprovementprojectsandfavorablemixthiswaspartiallyoffsetbyhighergainsin relatedtodivestituresprimarilythedivestitureofthesplendabrandadditionallyoperationsinvenezuela negativelyimpactedtheconsumersegmentincomebeforetaxinascomparedto intheconsumersegmentincomebeforetaxasapercenttosaleswasversusinprimarilydue tolowerdivestituregainsinversusintheconsumersegmenttaxincludedagainofbillionfrom divestituresprimarilythedivestitureofthesplendabrandintheconsumersegmentincludedagainbillion fromdivestituresprimarilythedivestitureofthekybrand pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswas versusintheincreaseinincomebeforetaxwasprimarilyduetostrongsalesvolumegrowthandfavorable sellingmarketingandadministrativeexpensesduetocostmanagementadditionallythefiscalyearhadhigher gainsofbillionrelatedtodivestiturespartiallyoffsetbyahigheriprdchargeofbillionascomparedto thefiscalyearofincludedthegainsfromthedivestituresofthecontrolledsubstancerawmaterialandapibusiness andcertainanestheticproductsineuropeversusthegainsrecordedinfromtheusdivestitureofnucynta inthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswasversusinthe favorableincomebeforetaxwasprimarilyduetohighergainsrecognizedinpartiallyoffsetbyasalesdeclineof olysiosovriadsimeprevirincreasedinvestmentspendingandnegativecurrencyimpactsascomparedto includedinwasagainofbillionontheusdivestitureofnucyntaaswellasreceiptofacontingent paymentandapositiveadjustmenttopreviousreserveestimatesincludingmanagedmedicaidrebatesadditionallythe pharmaceuticalsegmentincomebeforetaxinwasnegativelyimpactedbybillionforanadditionalyearofthe brandedprescriptiondrugfeeandhigherintangibleassetamortizationexpenseofbillionprimarilyrelatedtothe writedownofincivotelaprevir medicaldevicessegmentinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswas versusinthedecreaseintheincomebeforetaxasapercenttosaleswasprimarilyduetolowergainsof billionrelatedtodivestitureshigherlitigationexpenseofbillionandahigherrestructuringchargeofbillion ascomparedtothiswaspartiallyoffsetbyanintangibleassetwritedownofbillionrelatedtoacclarentin andfavorablesellingmarketingandadministrativeexpensesin johnsonjohnsonannualreportinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswasversusin primarilyduetoarestructuringchargeofbillionanintangibleassetwritedownofbillionrelatedtoacclarent andlowergainsofbillionondivestituresascomparedtointhemedicaldevicessegmentincluded gainsofbillionprimarilyforthedivestitureofthecordisbusinessversusagainofbillionrecordedinfor thedivestitureoftheorthoclinicaldiagnosticsbusinesstheincomebeforetaxwasfavorablyimpactedbylower netlitigationexpenseofbillionwhichincludedagainfromthelitigationsettlementagreementofbillionwith guidantandlowersynthesintegrationcostsofbillioninascomparedto restructuringthecompanyannouncedrestructuringactionsinitsmedicaldevicessegmentthatareexpectedtoresult inannualizedpretaxcostsavingsofmilliontobillionthemajorityofwhichisexpectedtoberealizedbythe endofapproximatelymillioninsavingswererealizedinthesavingswillprovidethecompanywith addedflexibilityandresourcestofundinvestmentinnewgrowthopportunitiesandinnovativesolutionsforcustomersand patientsthecompanyestimatesthatinconnectionwithitsplansitwillrecordpretaxrestructuringrelatedchargesof approximatelybilliontobillionmostofwhichareexpectedtobeincurredbytheendofinthe companyrecordedapretaxchargeofmillionofwhichmillionisincludedincostofproductssoldand millionisincludedinotherincomeexpenseinthecompanyrecordedapretaxchargeofmillionof whichmillionwasincludedincostofproductssoldrestructuringchargesofbillionhavebeenrecorded sincetherestructuringwasannouncedseenotetotheconsolidatedfinancialstatementsforadditionaldetails relatedtotherestructuring provisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheeffectivetaxratedecreasedbyascomparedtoasdescribedinnotetothe consolidatedfinancialstatementsthecompanyadoptedanewaccountingstandardforthereportingofadditionaltax benefitsonsharebasedcompensationthatvestedorwereexercisedduringthefiscalyeartheadoptionofthisnew standardreducedtheeffectivetaxrateforthefiscalbyversustheremainderofthechangeinthe effectivetaxratewasprimarilyrelatedtothelowerearningsbeforetaxesintheunitedstatesandthesettlementofseveral uncertaintaxpositionsinversus thedecreaseintheeffectivetaxrateascomparedtowasprimarilyattributabletotheincreasesintaxable incomeinlowertaxjurisdictionsrelativetohighertaxjurisdictionsandataxbenefitresultingfromarestructuringof internationalaffiliatesadditionallytheeffectivetaxratewasaffectedbytheitemsmentionedbelow theincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthedivestitureofthe orthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlowtaxratesthemixof earningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebrandedprescriptiondrug feewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreaseindividendsfromcurrent yearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxratewerepartiallyoffsetby ataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeandiiasettlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenue serviceauditoftaxyears liquidity capital resources liquiditycashflows cashandcashequivalentswerebillionattheendofascomparedtobillionattheendofthe primarysourcesandusesofcashthatcontributedtothebillionincreasewereapproximatelybillionofcash generatedfromoperatingactivitiesoffsetbybillionnetcashusedbyinvestingactivitiesandbillionnetcash usedbyfinancingactivitiesandbillionduetotheeffectonexchangeratechangesoncashandcashequivalentsin additionthecompanyhadbillioninmarketablesecuritiesattheendofandbillionattheendof seenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcashequivalentsandmarketable securities cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash expensesandotheradjustmentsfordepreciationandamortizationstockbasedcompensationandassetswritedowns reducedbybillionfromnetgainsonsaleofassetsbusinessesbillionrelatedtodeferredtaxesandbillion johnsonjohnsonannualreport relatedtoaccountsreceivableinventoriesandothercurrentandnoncurrentliabilitiesadditionalsourcesofoperating cashflowofbillionresultedfromanincreaseinaccountspayableandaccruedliabilitiesandadecreaseinother currentandnoncurrentassets investingactivitiesuseofbillionwasprimarilyforacquisitionsnetofcashacquiredofbillionandadditionsto propertyplantandequipmentofbillionthiswaspartiallyoffsetbyproceedsfromthenetsaleofinvestments primarilymarketablesecuritiesofbillionandbillionofproceedsfromthedisposalofassetsbusinesses financingactivitiesuseofbillionwasprimarilyfordividendstoshareholdersofbillionandbillionforthe repurchaseofcommonstockfinancingactivitiesalsoincludedasourceofbillionfromnetproceedsofshortand longtermdebtandbillionofproceedsfromstockoptionsexercisedemployeewithholdingtaxonstockawardsnet inthecompanyannouncedadefinitiveagreementtoacquireabbottmedicalopticsincforapproximately billionandonjanuarysubsequenttoyearendthecompanyannouncedadefinitivetransactionagreement toacquireactelionltdforapproximatelybillionabbottmedicalopticsclosedonfebruarythe companywillusecashheldbythecompanysforeignsubsidiariestopayfortheseacquisitions onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockasofjanuary billionhasbeenrepurchasedundertheprogramtherepurchaseprogramhasnotimelimitandmaybe delayedorsuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbeavailableforgeneralcorporate purposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailablecashandaccesstothe capitalmarketstheprevioussharerepurchaseprogramapprovedonjulyauthorizingthecompanytopurchase uptobillionofthecompanyssharesofcommonstockwascompletedonapril inthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketthecompanyhada shelfregistrationwiththeussecuritiesandexchangecommissionthatexpiredonfebruarythecompany planstofileanewshelfregistrationonfebruarywhichwillenableittoissuedebtsecuritiesonatimelybasis foradditionaldetailsonborrowingsseenotetotheconsolidatedfinancialstatements thecompanyanticipatesthatoperatingcashflowsexistingcreditfacilitiesandaccesstothecapitalmarketswillprovide sufficientresourcestofundoperatingneedsin concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccounts receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofjanuaryandbillion asofjanuaryapproximatelybillionasofjanuaryandapproximatelybillionasofjanuary ofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothecompanysconsumer visioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevicescustomerswhicharein linewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacted bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatjanuaryandbillionatjanuarythecompany continuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentswithinterestforcustomers wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosses onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar johnsonjohnsonannualreportfromthejanuarymarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthejanuarymarketrateswoulddecreasethe unrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterparties tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremote thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloating ratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbyapproximatelymillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingsbetweenandwasaresultoffinancingforthecompanyssharerepurchaseprogramandgeneral corporatepurposesinnetcashcashandcurrentmarketablesecuritiesnetofdebtwasbillioncompared tonetcashofbillionintotaldebtrepresentedoftotalcapitalshareholdersequityandtotaldebtin andoftotalcapitalinshareholdersequitypershareattheendofwascomparedto atyearendanincreaseof asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatements contractualobligationsandcommitments thecompanyscontractualobligationsareprimarilyforleasesdebtandunfundedretirementplanstherearenoother significantobligationstosatisfytheseobligationsthecompanywillusecashfromoperationsthefollowingtable summarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasofjanuaryseenotes andtotheconsolidatedfinancialstatementsforfurtherdetails intereston unfunded debt debt retirement operating dollarsinmillions obligations obligations plans leases total total fortaxmattersseenotetotheconsolidatedfinancialstatementsforotherretirementplanandpostemployment medicalbenefitinformationseenotetotheconsolidatedfinancialstatementsthetabledoesnotincludeactivity relatedtobusinesscombinations johnsonjohnsonannualreport dividends thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpershareinthedividendsweredistributed asfollows firstquarter secondquarter thirdquarter fourthquarter total onjanuarytheboardofdirectorsdeclaredaregularquarterlycashdividendofpersharepayableon marchtoshareholdersofrecordasoffebruarythecompanyexpectstocontinuethepracticeof payingregularcashdividends information criticalaccountingpoliciesandestimates managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompanys consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosures actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordeliveredand titleandriskoflosspasstothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscoupons productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsales arerecorded productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludethemedicaidrebateprovision areestimatedbasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarket conditionsinthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproducts primarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellas internallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand johnsonjohnsonannualreportpromotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebased incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold thecompanyalsoearnsservicerevenueforcopromotionofcertainproductsforallyearspresentedservicerevenues wereorlessofthetotalrevenuesandareincludedinsalestocustomersthesearrangementsareevaluatedto determinetheappropriateamountstobedeferredorrecordedasareductionofrevenue inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaborations reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchanges toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact belowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedjanuaryandjanuary consumersegment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset johnsonjohnsonannualreport pharmaceutical segment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset includesadjustments medicaldevicessegment balanceat balanceat beginningof payments endof dollarsinmillions period accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset johnsonjohnsonannualreportincometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilities thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atjanuaryandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatjanuaryandjanuarythecompanys foreignsubsidiariesheldbalancesofcashcashequivalentsandmarketablesecuritiesintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertain internationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthecompanyintendsto continuetoreinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatethese earningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompany doesnotdeterminethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnot practical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimatedadditionallythecompanyrecordsinsurancereceivableamountsfromthirdpartyinsurerswhen recoveryisprobableasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynot becollectedfromthirdpartyinsurers thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued seenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceedings longlivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumptions regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheserates andtheeffectaratechangetothehealthcarecosttrendwouldhaveonthecompanysresultsofoperations stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpected dividendyieldforperformanceshareunitsthefairmarketvalueiscalculatedforeachofthethreecomponentgoalsatthe dateofgrantthefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedon thedateofgrantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenot paidontheperformanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalof eachperformanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelseenoteto theconsolidatedfinancialstatementsforadditionalinformation johnsonjohnsonannualreport newaccountingpronouncements refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofjanuary economicandmarketfactors thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymakers consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcerns thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheunited statestheweightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproducts prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin venezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedinthefaceofincreasing coststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprogramsproductivityimprovementsand periodicpriceincreases thevenezuelangovernmenthasestablishedalternativesystemsandofferingsofvariousforeigncurrencyexchanges throughthefourthquarterofthenumberofthecompanystransactionsconductedattheofficialratedeclinedfrom priorquartersasaresultthecompanydeterminedthatitwasnolongerlikelythatalloutstandingnetmonetaryassets wouldbesettledattheofficialgovernmentrateofbolivaresfuertestooneusdollarthereforeinthe companyrecordedachargeofmilliontorevalueitsnetmonetaryassetsinvenezuelaatoneofthegovernments alternativeexchangeratessimadiandimpairitsnonmonetaryassetsaftertherevaluationasofjanuarythe companysvenezuelansubsidiariesrepresentedlessthanofthecompanysconsolidatedassetsandliabilities whilethecompanycontinuestodobusinessingreecethecompanycloselymonitorstheeconomicsituationasof januarythecompanysgreeksubsidiariesrepresentedandofthecompanysconsolidatedassets andrevenuesrespectively onjunetheunitedkingdomukheldareferenduminwhichvotersapprovedanexitfromtheeuropean unioneucommonlyreferredtoasbrexitgiventhelackofcomparableprecedentitisunclearwhatfinancialtrade regulatoryandlegalimplicationsthewithdrawaloftheukfromtheeuwillhavebrexitcreatesglobalpoliticaland economicuncertaintywhichmaycauseamongotherconsequencesvolatilityinexchangeratesandinterestrates additionalcostcontainmentbythirdpartypayorsandchangesinregulationshoweverthecompanycurrentlydoesnot believethattheseandotherrelatedeffectswillhaveamaterialimpactonthecompanysconsolidatedfinancialpositionor operatingresultsasofjanuarythebusinessofthecompanysuksubsidiariesrepresentedlessthanof boththecompanysconsolidatedassetsandfiscaltwelvemonthsrevenues thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandincomebymillion governmentsaroundtheworldincludingintheunitedstatesconsidervariousproposalstomakechangestotaxlaws whichmayincludeincreasingordecreasingexistingstatutorytaxratesachangeinstatutorytaxrateinanycountrywould resultintherevaluationofthecompanysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictioninthe periodinwhichthenewtaxlawisenactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanys consolidatedstatementofearningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhere itoperateschangestothestatutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybe materialtothefiscalquarterandyearinwhichthelawchangeisenacted thebelgiangovernmentiscurrentlyconsideringaproposedchangetoitscorporatetaxcodeincludingaproposalto loweritsstatutorytaxrateifenactedtheproposedchangewouldresultinrevaluationofthecompanysdeferredtax assetswithacorrespondingchargetotaxexpensethatmayhaveamaterialeffectonthecompanysresultsofoperations fortheperiodbasedonthedeferredtaxassetbalancesasofjanuarythecompanyestimatesforeverythat thestatutorytaxisloweredtherewillbeadditionalonetimetaxexpenseofapproximatelymillionasignificant portionofthedeferredtaxassetdescribedasinternationalrdcapitalizedfortaxinnotetotheconsolidated financialstatementsisrelatedtothecompanysoperationsinbelgium johnsonjohnsonannualreporttheusgovernmentiscurrentlyconsideringvariousproposalstochangesinitscorporatetaxcodetheseproposals includebutarenotlimitedtoloweringthestatutorytaxrateandtherulesonhowinternationalincomeearnedbythe companyistaxedintheustheimpactoftheseproposalsmayhaveamaterialeffectonthecompanysresultsof operationsfortheperiodandonfutureperiods asthebelgianorusgovernmentsarestillconsideringtheseproposalsitisnotcertainwhenoriftheywillbeenacted thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare products changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaying medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompanys businesses thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefiled abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenged thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplaceforfurtherinformationseethe discussiononremicaderelatedcasesandlitigationagainstfilersofabbreviatednewdrugapplicationsin notetotheconsolidatedfinancialstatements legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertain litigationmattersandcontinuestomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther developmentsinaccordancewithaccountingstandardscodificationascfortheseandotherlitigation andregulatorymatterscurrentlydisclosedforwhichalossisprobableorreasonablypossiblethecompanyisunableto estimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccruedforlegalcontingencies oftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyonestimatesand assumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolved inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceedings johnsonjohnsonannualreport commonstockmarketprices thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompanythecompositemarketpricerangesfor johnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnsonjohnsonannualreportitem quantitative qualitative disclosures market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarketrisk ofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statements supplementary data indextoauditedconsolidatedfinancialstatements consolidatedbalancesheets consolidatedstatementsofearnings consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflows notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporting johnsonjohnsonannualreport johnson johnson subsidiaries consolidated balance sheets atjanuaryandjanuary dollarsinmillionsexceptshareandpershareamountsnote assets currentassets cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccounts inventoriesnotesand prepaidexpensesandotherreceivables totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherassets totalassets liabilitiesandshareholdersequity currentliabilities loansandnotespayablenote accountspayable accruedliabilities accruedrebatesreturnsandpromotions accruedcompensationandemployeerelatedobligations accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilities totalliabilities shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshares commonstockparvaluepersharenoteauthorizedsharesissued shares accumulatedothercomprehensiveincomenote retainedearnings lesscommonstockheldintreasuryatcostnotesharesandshares totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements earnings dollarsandsharesinmillionsexceptpershareamountsnote salestocustomers costofproductssold grossprofit sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearnings netearningspersharenotesand basic diluted cashdividendspershare averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements comprehensive income dollarsinmillionsnote netearnings othercomprehensiveincomelossnetoftax foreigncurrencytranslation securities unrealizedholdinggainlossarisingduringperiod reclassificationstoearnings netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerates netchange derivativeshedges unrealizedgainlossarisingduringperiod reclassificationstoearnings netchange othercomprehensiveincomeloss comprehensiveincome thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelysecurities millionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements equity dollarsinmillionsnote accumulated common stock treasury retained comprehensive issued stock total earnings income amount amount balancedecember netearnings cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearnings cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearnings cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements cash flows dollarsinmillionsnote cashflowsfromoperatingactivities netearnings adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities depreciationandamortizationofpropertyandintangibles stockbasedcompensation venezuelaadjustments assetwritedowns netgainonsaleofassetsbusinesses deferredtaxprovision accountsreceivableallowances changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestitures increaseinaccountsreceivable increaseininventories increaseinaccountspayableandaccruedliabilities decreaseinothercurrentandnoncurrentassets decreaseincreaseinothercurrentandnoncurrentliabilities netcashflowsfromoperatingactivities cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestments salesofinvestments otherprimarilyintangibles netcashusedbyinvestingactivities cashflowsfromfinancingactivities dividendstoshareholders repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalents increasedecreaseincashandcashequivalents cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalized incometaxes supplementalscheduleofnoncashinvestingandfinancingactivities treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockawards conversionofdebt acquisitions fairvalueofassetsacquired fairvalueofliabilitiesassumedandnoncontrollinginterests netcashpaidforacquisitions seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportnotes consolidated financial statements summary significant accounting policies principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminated descriptionofthecompanyandbusinesssegments thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautypreviouslyreferredtoas skincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedto thegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentis focusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscienceoncologyandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgerycardiovasculardiabetescareandvisioncarefieldswhicharedistributedtowholesalershospitals andretailersandusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsand clinics newaccountingpronouncements recentlyadoptedaccountingpronouncements duringthefiscalfirstquarterofthefinancialaccountingstandardsboardfasbissuedaccountingstandards updatecompensationstockcompensationimprovementstoemployeesharebasedpaymentaccounting theamendmentsintheupdateareeffectiveforannualperiodsbeginningafterdecemberandinterimperiods withinthoseannualperiodsearlyadoptionispermittedforanyentityinanyinterimorannualperiodduringthefiscal secondquarterofthecompanyelectedtoearlyadoptthisstandardtheupdaterequiresthefollowingchangesto presentationofthefinancialstatements allexcesstaxbenefitsanddeficienciestoberecognizedasareductionoranincreasetotheprovisionfortaxeson incomepreviouslythecompanyrecordedthesebenefitsdirectlytoretainedearningsthetaxbenefitforthe companywasmillionforthefiscalyearthestandarddoesnotpermitretroactivepresentationofthis benefittopriorfiscalyearsontheconsolidatedstatementofearnings thetaxbenefitordeficiencyisrequiredtobeclassifiedandpresentedasacashflowtofromoperatingactivitiesitwas previouslyrequiredtobepresentedasacashflowtofromfinancingactivitiesontheconsolidatedstatementofcash flowsaspermittedinthestandardthecompanyhaselectedtoadoptthisreclassificationonaprospectivebasisand thereforepriorfiscalyearsfortheconsolidatedstatementofcashflowshavenotbeenrecastforthisprovision clarifiesthatallcashpaymentsmadetotaxingauthoritiesonemployeessharebasedcompensationshouldbe classifiedasacashoutflowfromfinancingactivitiesthisreclassificationisrequiredtoberecastretrospectivelyasa resultforthefiscalyearmillionwasclassifiedasacashoutflowfromfinancingactivitiesandmillion andmillionofcashoutflowwasreclassifiedfromanoperatingactivitytoafinancingactivityproceedsfromthe exerciseofstockoptionsemployeewithholdingtaxonstockawardsnetinthefiscalyearsand respectively inthedilutednetearningspersharecalculationwhenapplyingthetreasurystockmethodforsharesthatcouldbe repurchasedtheassumedproceedsnolongerincludetheamountofexcesstaxbenefitthisdidnothaveamaterial impactonthecompanysdilutednetearningspersharecalculation duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdatesimplifyingthe presentationofdebtissuancecoststhisupdaterequirescapitalizeddebtissuancecoststobepresentedasareduction johnsonjohnsonannualreport tothecarryingvalueofdebtinsteadofbeingclassifiedasadeferredchargethisupdateiseffectiveforthecompanyfor allannualandinterimperiodsbeginningafterdecemberandisrequiredtobeappliedretroactivelyforallperiods presentedthisupdatedidnothaveamaterialimpactonthepresentationofthecompanysfinancialposition duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatebusinesscombinations simplifyingtheaccountingformeasurementperiodadjustmentstheamendmentsinthisupdaterequirethatanacquirer recognizeadjustmentstoprovisionalamountsthatareidentifiedduringthemeasurementperiodinthereportingperiodin whichtheadjustmentamountsaredeterminedthisupdateiseffectiveforthecompanyforallannualandinterimperiods beginningafterdecembertheamendmentsinthisupdateshouldbeappliedprospectivelytoadjustmentsto provisionalamountsthatoccuraftertheeffectivedateofthisupdatewithearlierapplicationpermittedforfinancial statementsthathavenotbeenissuedthisupdatedidnothaveamaterialimpactonthecompanysconsolidatedfinancial statements duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatenodisclosureof uncertaintiesaboutanentitysabilitytocontinueasagoingconcernthisstandardrequiresmanagementtoevaluate foreachannualandinterimreportingperiodwhetherthereareconditionsandeventsconsideredintheaggregatethat raisesubstantialdoubtaboutanentitysabilitytocontinueasagoingconcernwithinoneyearafterthedatethefinancial statementsareissuedorareavailabletobeissuedifsubstantialdoubtisraisedadditionaldisclosuresaround managementsplantoalleviatethesedoubtsarerequiredthisupdatebecomeseffectiveforallannualperiodsandinterim reportingperiodsendingafterdecembertheadoptionofthisstandarddidnothaveanyimpactonthe companyscurrentdisclosuresinthefinancialstatements recentlyissuedaccountingpronouncements notadoptedasofjanuary duringthefiscalfirstquarterofthefasbissuedaccountingstandardupdateclarifyingthedefinitionof abusinessthisupdatenarrowsthedefinitionofabusinessbyprovidingascreentodeterminewhenanintegratedsetof assetsandactivitiesisnotabusinessthescreenspecifiesthatanintegratedsetofassetsandactivitiesisnotabusiness ifsubstantiallyallofthefairvalueofthegrossassetsacquiredordisposedofisconcentratedinasingleoragroupof similaridentifiableassetsthisupdatewillbeeffectiveforthecompanyforannualperiodsbeginningafterdecember includinginterimperiodswithinthoseannualperiodsearlyadoptionispermittedthisupdateshouldbeapplied prospectivelythecompanyiscurrentlyassessingtheimpactofthefutureadoptionofthisstandardonitsfinancial statements duringthefiscalfirstquarterofthefasbissuedaccountingstandardupdatesimplifyingthetestfor goodwillimpairmentthisupdatesimplifieshowanentityisrequiredtotestgoodwillforimpairmentagoodwill impairmentwillnowbemeasuredbytheamountbywhichareportingunitscarryingvalueexceedsitsfairvaluenotto exceedthecarryingamountofgoodwillthisupdatewillbeeffectiveforthecompanyforitsannualoranyinterimgoodwill impairmenttestsinfiscalyearsbeginningafterdecemberearlyadoptionispermittedthisupdateshouldbe appliedprospectivelythecompanyiscurrentlyassessingtheimpactofthefutureadoptionofthisstandardonits financialstatements duringthefiscalfirstquarterofthefasbissuedaccountingstandardupdateotherincomegainsand lossesfromthederecognitionofnonfinancialassetsthisupdateclarifiesthescopeofassetderecognitionguidance addsguidanceforpartialsalesofnonfinancialassetsandclarifiesrecognizinggainsandlossesfromthetransferof nonfinancialassetsincontractswithnoncustomersthisupdatewillbeeffectiveforthecompanyforitsannualandinterim reportingperiodsbeginningafterdecemberthesametimeastheamendmentsinupdaterevenue fromcontractswithcustomersthisupdateallowsthecompanytochooseeitherafullretrospectivemethodormodified retrospectivemethoduponadoptionthecompanyiscurrentlyassessingtheimpactofthefutureadoptionofthis standardonitsfinancialstatements duringthefiscalfirstquarterofthefasbissuedaccountingstandardsupdatefinancialinstruments recognitionandmeasurementoffinancialassetsandfinancialliabilitiestheamendmentsinthisupdatesupersedethe guidancetoclassifyequitysecuritieswithreadilydeterminablefairvaluesintodifferentcategoriesthatistradingor availableforsaleandrequireequitysecuritiestobemeasuredatfairvaluewithchangesinthefairvaluerecognized throughnetincomethestandardamendsfinancialreportingbyprovidingrelevantinformationaboutanentitysequity investmentsandreducingthenumberofitemsthatarerecognizedinothercomprehensiveincomethisupdatewillbe effectiveforthecompanyforannualperiodsbeginningafterdecemberandinterimperiodswithinthoseannual periodsthecompanyisunabletoestimatetheimpactofthefutureadoptionofthisstandardonitsfinancialstatements asitwilldependontheequityinvestmentsasoftheadoptiondate johnsonjohnsonannualreportduringthefiscalfirstquarterofthefasbissuedaccountingstandardsupdateleasestopicthis updaterequirestherecognitionofleaseassetsandleaseliabilitiesonthebalancesheetforallleaseobligationsand disclosingkeyinformationaboutleasingarrangementsthisupdaterequirestherecognitionofleaseassetsandlease liabilitiesbylesseesforthoseleasesclassifiedasoperatingleasesundercurrentgenerallyacceptedaccountingprinciples thisupdatewillbeeffectiveforthecompanyforallannualandinterimperiodsbeginningafterdecember includinginterimperiodswithinthosefiscalyearsearlyapplicationispermittedtheupdateisrequiredtobeadoptedusing amodifiedretrospectiveapproachthecompanyanticipatesthatmostofitsoperatingleaseswillresultintherecognitionof additionalassetsandthecorrespondingliabilitiesonitsconsolidatedbalancesheetshoweverdoesnotexpecttohavea materialimpactonthefinancialpositiontheactualimpactwilldependonthecompanysleaseportfolioatthetimeof adoptionthecompanycontinuestoassessallimplicationsofthestandardandrelatedfinancialdisclosures duringthefiscalfirstquarterofthefasbissuedaccountingstandardsupdateinvestmentsequity methodandjointventurestopicsimplifyingthetransitiontotheequitymethodofaccountingtheamendments intheupdateeliminatetherequirementthatwhenaninvestmentqualifiesfortheuseoftheequitymethodasaresultofan increaseinthelevelofownershipinterestordegreeofinfluenceaninvestormustadjusttheinvestmentresultsof operationsandretainedearningsretroactivelyonastepbystepbasisasiftheequitymethodhadbeenineffectduringall previousperiodsthattheinvestmenthadbeenheldtheamendmentsinthisupdateareeffectiveforallentitiesforfiscal yearsandinterimperiodswithinthosefiscalyearsbeginningafterdecembertheamendmentsshouldbe appliedprospectivelyupontheireffectivedatetoincreasesinthelevelofownershipinterestordegreeofinfluencethat resultintheapplicationoftheequitymethodearlieradoptionispermittedforanyentityinanyinterimorannualperiod theadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthepresentationofthecompanys consolidatedfinancialstatements duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatestatementofcash flowstopicclassificationofcertaincashreceiptsandcashpaymentsthisupdateaddresseswhetherto presentcertainspecificcashflowitemsasoperatinginvestingorfinancingactivitiestheamendmentsinthisupdateare effectiveforpublicentitiesforfiscalyearsandinterimperiodswithinthosefiscalyearsbeginningafterdecember earlyadoptionispermittedincludingadoptioninaninterimperiodthecompanyiscurrentlyassessingtheimpact ofthefutureadoptionofthisstandardonitsconsolidatedstatementsofcashflows duringthefiscalfourthquarterofthefasbissuedaccountingstandardsupdateincometaxestopic intraentitytransfersofassetsotherthaninventorythisupdateremovesthecurrentexceptioninusgaap prohibitingentitiesfromrecognizingcurrentanddeferredincometaxexpensesorbenefitsrelatedtotransferofassets otherthaninventorywithintheconsolidatedentitythecurrentexceptiontodefertherecognitionofanytaximpactonthe transferofinventorywithintheconsolidatedentityuntilitissoldtoathirdpartyremainsunaffectedtheamendmentsin thisupdateareeffectiveforpublicentitiesforannualreportingperiodsbeginningafterdecemberearlyadoption ispermittedandshouldbeinthefirstinterimperiodifanentityissuesinterimfinancialstatementsthecompanyis currentlyassessingtheimpactofthefutureadoptionofthisstandardonitsconsolidatedfinancialstatements duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdatesimplifyingthe measurementofinventorythisupdaterequiresinventorytobemeasuredatthelowerofcostornetrealizablevaluenet realizablevalueistheestimatedsellingpricesintheordinarycourseofbusinesslessreasonablypredictablecostsof completiondisposalandtransportationthisupdatewillbeeffectiveforthecompanyforallannualandinterimperiods beginningafterdecembertheamendmentsinthisupdateshouldbeappliedprospectivelywithearlier applicationpermittedasofthebeginningofaninterimorannualreportingperiodthisupdatewillnothaveamaterial impactonthepresentationofthecompanysfinancialposition duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdaterevenuefrom contractswithcustomerswhichalongwithamendmentsissuedinandwillreplacesubstantiallyallcurrent usgaapguidanceonthistopicandeliminateindustryspecificguidanceearlyadoptionofthisstandardispermitted butnotbeforetheoriginaleffectivedateforallannualperiodsandinterimreportingperiodsbeginningafterdecember theguidancepermitstwomethodsofadoptionfullretrospectivemethodretrospectiveapplicationtoeachprior reportingperiodpresentedormodifiedretrospectivemethodretrospectiveapplicationwiththecumulativeeffectof initiallyapplyingtheguidancerecognizedatthedateofinitialapplicationandprovidingcertainadditionaldisclosures whilethecompanycontinuestoevaluatetheeffectofthestandardpreliminarilyitdoesnotanticipateamaterialimpact onitsfinancialstatementstocompletetheassessmentoftheimpactofthestandardtothefinancialstatementsthe companycontinuestoassessallimplicationsofthestandardmethodofadoptionandrelatedfinancialdisclosures additionallythecompanycontinuestomonitormodificationsclarificationsandinterpretationsissuedbythefasbthat mayaffectcurrentconclusions johnsonjohnsonannualreport cashequivalents thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrras rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonths fromthedateofpurchaseareclassifiedasmarketablesecurities investments investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsalearecarriedatestimatedfairvaluewithunrealizedgains andlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsalesecuritiesavailable forcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongtermmanagementdetermines theappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeofpurchaseandreevaluatessuch determinationateachbalancesheetdatethecompanyperiodicallyreviewsitsinvestmentsinequitysecuritiesfor impairmentandadjuststheseinvestmentstotheirfairvaluewhenadeclineinmarketvalueisdeemedtobeotherthan temporaryiflossesonthesesecuritiesareconsideredtobeotherthantemporarythelossisrecognizedinearnings propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheassets buildingandbuildingequipment years landandleaseholdimprovements years machineryandequipment years thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflows revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss passtothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscouponsproductreturnsand discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorded productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludemedicaidareestimatedbased oncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevarious marketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughthe analysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygenerated information salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnsaccruals johnsonjohnsonannualreportsalesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewithusgaap guidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsalesvaluesales returnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsforcertain franchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualsalestocustomersduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebased incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare soldthecompanyalsoearnsservicerevenueforcopromotionofcertainproductsandincludesitinsalestocustomers thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedasareductionof revenue shippingandhandling shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresented inventories inventoriesarestatedatthelowerofcostormarketdeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaired intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstruments asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instruments johnsonjohnsonannualreport productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecomes availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts areprobableandcanbereasonablyestimated asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimatedbasedontheavailabilityofpriorcoveragereceivablesforinsurance recoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethatarecoverywill berealizedasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynotbe collectedfromthirdpartyinsurers concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccounts receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofjanuaryand approximatelybillionasofjanuaryapproximatelybillionasofjanuaryandapproximately billionasofjanuaryofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothe companysconsumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevices customerswhichareinlinewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacted bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatjanuaryandbillionatjanuarythecompany continuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentswithinterestforcustomers wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredupfrontandmilestonepaymentsmadetothirdpartiesin connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful lifeoftherelatedproductamountscapitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulated amortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract johnsonjohnsonannualreportdevelopmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollows naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomers royaltiesmilestonespaidtocollaborativepartner costofproductssold postregulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidated researchanddevelopmentexpense thecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarketed withpharmacyclicsllcanabbviecompany advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively incometaxes incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atjanuaryandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatjanuaryandjanuarythecompanys foreignsubsidiariesheldbalancesofcashcashequivalentsandmarketablesecuritiesintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertain internationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthecompanyintendsto continuetoreinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatethese earningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompany doesnotdeterminethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnot practical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod johnsonjohnsonannualreport useofestimates thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxesdepreciation amortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresultsmayormaynot differfromthoseestimates thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks andthereforeincludesadditionalshippingdaysaswasthecaseinandwillbethecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation cash cash equivalents current marketable securities attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof cash current carrying unrecognized unrecognized estimated cash marketable dollarsinmillions amount gain loss fairvalue equivalents securities cash usgovtsecurities othersovereignsecurities usreverserepurchase agreements otherreverserepurchase agreements corporatedebtsecurities moneymarketfunds timedeposits subtotal unrealized unrealized gain loss govtsecurities othersovereignsecurities corporatedebtsecurities equityinvestments subtotalavailablefor sale totalcashcashequivalents andcurrentmarketable securities johnsonjohnsonannualreport current carrying unrecognized unrecognized estimated cash marketable dollarsinmillions amount gain loss fairvalue equivalents securities cash usgovtsecurities othersovereignsecurities usreverserepurchase agreements otherreverserepurchase agreements corporatedebtsecurities moneymarketfunds timedeposits subtotal unrealized unrealized gain loss govtsecurities othersovereignsecurities corporatedebtsecurities subtotalavailablefor sale totalcashcashequivalents andcurrentmarketable securities heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings availableforsalesecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinothercomprehensive income fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinputs thecontractualmaturitiesoftheavailableforsaledebtsecuritiesatjanuaryareasfollows cost fair dollarsinmillions basis value duewithinoneyear dueafteroneyearthroughfiveyears dueafterfiveyearsthroughtenyears totaldebtsecurities thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrating inventories attheendofandinventorieswerecomprisedof dollarsinmillions rawmaterialsandsupplies goodsinprocess finishedgoods totalinventories johnsonjohnsonannualreport property plant equipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillions landandlandimprovements buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestwasbillioninand uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulated depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearnings intangible assets goodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillions intangibleassetswithdefinitelives patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelives trademarks purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelives totalintangibleassetsnet goodwillasofjanuaryandjanuaryasallocatedbysegmentofbusinesswasasfollows dollarsinmillions consumer pharmaceutical meddevices total goodwillatdecember goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatjanuary goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatjanuary johnsonjohnsonannualreporttheweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetsincludedincostof productssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsendedjanuary januaryanddecemberrespectivelytheestimatedamortizationexpenseincludingabbottmedical opticsamoforthefivesucceedingyearsapproximatesbillionbeforetaxperyearintangibleassetwritedowns areincludedinotherincomeexpensenet seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures fair value measurements thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterials denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsthecompanyalsousesequitycollarcontractstomanageexposuretomarketrisk associatedwithcertainequityinvestmentsallthreetypesofderivativesaredesignatedascashflowhedges additionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaretreatedasfairvaluehedgesthecompanyusesforwardforeignexchangecontracts designatedasnetinvestmenthedgesadditionallythecompanyusesforwardforeignexchangecontractstooffsetits exposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeignexchangecontractsarenotdesignatedas hedgesandthereforechangesinthefairvaluesofthesederivativesarerecognizedinearningstherebyoffsettingthe currentearningseffectoftherelatedforeigncurrencyassetsandliabilities thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesorrequirementstopostcollateralexcludingequitycollarcontractbyeitherthecompany orthecounterpartyforequitycollarcontractsthecompanypledgedtheunderlyinghedgedmarketableequitysecurities tothecounterpartyascollateralonanongoingbasisthecompanymonitorscounterpartycreditratingsthecompany considerscreditnonperformancerisktobelowbecausethecompanyprimarilyentersintoagreementswithcommercial institutionsthathaveatleastaninvestmentgradecreditratingrefertothetableonsignificantfinancialassetsand liabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercialinstitutions asofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchangecontractscross currencyinterestrateswapsinterestrateswapsandequitycollarcontractsofbillionbillionbillionand billionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivatives areexpectedtobehighlyeffectivechangesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransactiongainsandlossesassociatedwith interestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesininterestratesarerecordedto interestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestmenthedgesareaccountedforthrough thecurrencytranslationaccountonanongoingbasisthecompanyassesseswhethereachderivativecontinuestobe highlyeffectiveinoffsettingchangesofhedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffective hedgeaccountingisdiscontinuedhedgeineffectivenessifanyisincludedincurrentperiodearningsinotherincome expensenetforforwardforeignexchangecontractscrosscurrencyinterestrateswapsnetinvestmenthedgesandequity collarcontractsforinterestrateswapsdesignatedasfairvaluehedgeshedgeineffectivenessifanyisincludedin currentperiodearningswithininterestexpenseforthecurrentreportingperiodhedgeineffectivenessassociatedwith interestrateswapswasnotmaterial duringthefiscalsecondquarterofthecompanydesignateditseurodenominatednotesissuedinmaywith duedatesrangingfromtoasanetinvestmenthedgeofthecompanysinvestmentsincertainofits internationalsubsidiariesthatusetheeuroastheirfunctionalcurrencyinordertoreducethevolatilitycausedbychanges inexchangeratesduringthechangeinthecarryingvalueduetoremeasurementoftheseeuronotesresultedina millionpretaxgainreflectedinforeigncurrencytranslationadjustmentwithintheconsolidatedstatementsof comprehensiveincome johnsonjohnsonannualreport asofjanuarythebalanceofdeferrednetlossesonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexcluding interestratecontractsnetinvestmenthedgesandequitycollarcontractstheamountultimatelyrealizedinearningsmay differasforeignexchangerateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesat maturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesdesignatedascashflowhedgesforthefiscalyears endedjanuaryandjanuary gainloss gainloss gainloss reclassifiedfrom recognizedin recognizedin accumulatedoci dollarsinmillions accumulatedoci intoincome incomeexpense cashflowhedgesbyincomestatementcaption salestocustomers costofproductssold researchanddevelopmentexpense interestincomeinterestexpensenet otherincomeexpensenet total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion forwardforeignexchangecontracts crosscurrencyinterestrateswaps includesequitycollarcontracts forthefiscalyearsendedjanuaryandjanuaryalossofmillionandalossofmillion respectivelywasrecognizedinotherincomeexpensenetrelatingtoforwardforeignexchangecontractsnot designatedashedginginstruments fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbased measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequire revisedvaluationsunderthisstandardthatarerecognizedatfairvalue thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilities levelsignificantotherobservableinputs levelsignificantunobservableinputs johnsonjohnsonannualreportthecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofjanuaryandjanuary wereasfollows dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets forwardforeignexchangecontracts interestratecontracts total liabilities forwardforeignexchangecontracts interestratecontracts equitycollarcontracts total derivativesnotdesignatedashedginginstruments assets forwardforeignexchangecontracts liabilities forwardforeignexchangecontracts availableforsaleotherinvestments equityinvestments debtsecurities assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassified aslevel includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingjanuaryandjanuary respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingjanuaryandjanuary respectively includescrosscurrencyinterestrateswapsandinterestrateswaps classifiedasnoncurrentotherassetswiththeexceptionofmillionofcurrentassetsforjanuarythecarryingamount oftheequityinvestmentsweremillionandmillionasofjanuaryandjanuaryrespectivelytheunrealized gainsweremillionandmillionasofjanuaryandjanuaryrespectivelytheunrealizedlosseswere millionandmillionasofjanuaryandjanuaryrespectively classifiedascurrentmarketablesecurities classifiedasothercurrentassets classifiedasaccountspayable seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowings thecomponentsoflongtermdebtareasfollows effective effective dollarsinmillions rate rate notesdue monthliborfrndue notesdue debenturesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue notesdue notesduebeuro debenturesdue notesdue notesdue notesduemmeuro notesduemmgbpmmgbp notesdue notesduemmeuro notesdue debenturesdue notesdue notesduebeuro notesdue notesdue debenturesdue debenturesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt weightedaverageeffectiverate johnsonjohnsonannualreport translationrateatjanuary translationrateatjanuary theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinputs thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementsarenotmaterial throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiaries throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiaries aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillions income taxes theprovisionfortaxesonincomeconsistsof dollarsinmillions currentlypayable ustaxes internationaltaxes totalcurrentlypayable deferred ustaxes internationaltaxes totaldeferred provisionfortaxesonincome johnsonjohnsonannualreport acomparisonofincometaxexpenseattheusstatutoryrateofinandtothecompanys effectivetaxrateisasfollows dollarsinmillions us international earningsbeforetaxesonincome taxrates usstatutoryrate internationaloperationsexcludingireland irelandandpuertoricooperations researchandorphandrugtaxcredits usstateandlocal usmanufacturingdeduction ustaxoninternationalincome additionaltaxbenefitsonsharebasedcompensation ustaxbenefitonassetbusinessdisposals allother effectivetaxrate thecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentives theeffectivetaxratedecreasedbyascomparedtoasdescribedinnotethecompanyadopteda newaccountingstandardforthereportingofadditionaltaxbenefitsonsharebasedcompensationthatvestedorwere exercisedduringthefiscalyeartheadoptionofthisnewstandardreducedtheeffectivetaxrateoffiscalby versus theremainderofthechangeintheeffectivetaxratewasprimarilyrelatedtothelowerearningsbeforetaxesintheunited statesandthesettlementofseveraluncertaintaxpositionsinversus thedecreaseintheeffectivetaxrateascomparedtowasprimarilyattributabletotheincreasesintaxable incomeinlowertaxjurisdictionsrelativetohighertaxjurisdictionsandataxbenefitresultingfromarestructuringof internationalaffiliatesadditionallytheeffectivetaxratewasaffectedbytheitemsmentionedbelow theincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthedivestitureofthe orthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlowtaxratesthemixof earningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebrandedprescriptiondrug feewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreaseindividendsfromcurrent yearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxratewerepartiallyoffsetby ataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeandiiasettlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenue serviceauditoftaxyearstheimpactofthesettlementisreflectedintheustaxoninternationalincome andtheallotherlineitemswithintheabovereconciliation theitemsnotedabovereflectthekeydriversoftheratereconciliation johnsonjohnsonannualreporttemporarydifferencesandcarryforwardsforandwereasfollows deferredtax deferredtax dollarsinmillions asset liability asset liability employeerelatedobligations stockbasedcompensation depreciation nondeductibleintangibles internationalrdcapitalizedfortax reservesliabilities incomereportedfortaxpurposes netoperatinglosscarryforwardinternational miscellaneousinternational miscellaneousus totaldeferredincometaxes netofavaluationallowancerelatedtobelgiumofmillioninthisallowancewasreversedandtherelateddeferredtax assetwasutilizedtoreducecurrenttaxexpense thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincomesufficienttoutilizethesedeferredtaxassets thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits dollarsinmillions beginningofyear increasesrelatedtocurrentyeartaxpositions increasesrelatedtopriorperiodtaxpositions decreasesrelatedtopriorperiodtaxpositions settlements lapseofstatuteoflimitations endofyear theunrecognizedtaxbenefitsofbillionatjanuaryifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits inprogresswithanumberoftaxauthoritiestheirshascompleteditsauditforthetaxyearsthroughandis currentlyauditingthetaxyearsinothermajorjurisdictionswherethecompanyconductsbusinesstheyears remainopengenerallybacktotheyearthecompanybelievesitispossiblethatauditsmaybecompletedbytax authoritiesinsomejurisdictionsoverthenexttwelvemonthshoweverthecompanyisnotabletoprovideareasonably reliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxpositions thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilities interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestexpenseofmillionmillionandmillioninandrespectivelythe totalamountofaccruedinterestwasmillionandmillioninandrespectively johnsonjohnsonannualreport employee related obligations attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillions pensionbenefits postretirementbenefits postemploymentbenefits deferredcompensation totalemployeeobligations lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheets pensions benefit plans thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependents manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployeescompensation duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofserviceinthecompanyannounced thattheusdefinedbenefitplanwasamendedtoadoptanewbenefitformulaeffectiveforemployeeshiredonorafter januarythebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof service internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovided thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecostcredit amortizationofnettransitionobligation recognizedactuariallosses curtailmentsandsettlements netperiodicbenefitcost johnsonjohnsonannualreportamountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillions amortizationofnettransitionobligation amortizationofnetactuariallosses amortizationofpriorservicecredit unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgains andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment thefollowingtablerepresentstheweightedaverageactuarialassumptions retirementplans otherbenefitplans worldwidebenefitplans netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevels expectedlongtermrateofreturnonplanassets benefitobligation discountrate rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesforthefiscalyear thecompanychangeditsmethodologyindeterminingserviceandinterestcostfromthesingleweightedaverage discountrateapproachtodurationspecificspotratesalongthatyieldcurvetotheplansliabilitycashflowswhich managementhasconcludedisamorepreciseestimatepriortothischangeinmethodologythecompanymeasured serviceandinterestcostsutilizingasingleweightedaveragediscountratederivedfromtheyieldcurveusedtomeasure theplanobligationsthecompanyhasaccountedforthischangeasachangeinaccountingestimateandaccordingly hasaccountedforitonaprospectivebasisthischangedoesnotimpactthebenefitobligationanddidnothavea materialimpacttothefullyearresults theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsources longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividuals healthcareplans healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillions pointincrease pointdecrease healthcareplans totalinterestandservicecost postretirementbenefitobligation thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplans otherbenefit retirementplans plans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuarialgainslosses divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnonplanassets companycontributions planparticipantcontributions settlements divestituresacquisitions benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear inthecompanyofferedavoluntarylumpsumpaymentoptionbelowapredeterminedthresholdforcertaineligibleformer employeeswhoarevestedparticipantsoftheusqualifieddefinedbenefitpensionplanthedistributionofthelumpsumswas johnsonjohnsonannualreportsubstantiallycompletedbytheendoffiscaltheamountdistributedinwasapproximatelymillionthesedistributions fromtheplandidnothaveamaterialimpactonthecompanysfinancialposition otherbenefit retirementplans plans dollarsinmillions amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerates totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticeas fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunded inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplans nonqualifiedplans fundedplans unfundedplans dollarsinmillions planassets projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplans thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamounts donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillions projectedfuturecontributions johnsonjohnsonannualreport eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretirees durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplans permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefunds thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follows percentof target planassets allocation worldwideretirementplans equitysecurities debtsecurities totalplanassets determinationoffairvalueofplanassets theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquoted marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilities equityordebtpricesforeignexchangeratesandcreditcurves whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetassetvalue navprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsownedbythe fundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceinamarket thatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified aslevelleveldebtinstrumentsarepricedbasedonunobservableinputs johnsonjohnsonannualreport equitysecuritiescommonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorthenav isbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthendividedbythenumberof sharesoutstandingassetsinthelevelcategoryhaveaquotedmarketprice insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforpricing otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprices significant inactive significant investments marketsfor observable unobservable measuredat identicalassets inputs inputsa netasset level level level valueb totalassets dollarsinmillions shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds insurancecontracts otherassets investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresented b peradoptionofasucertaininvestmentsthataremeasuredatfairvalueusingthenetassetvaluepershareorits equivalentpracticalexpedienthavenotbeenclassifiedinthefairvaluehierarchyasperasuprioryearamountshavebeen reclassifiedtoconformtothecurrentyearpresentationthefairvalueamountspresentedinthistableareintendedtopermit reconciliationofthefairvaluehierarchytothetotalretirementplanassets thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember savings plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively johnsonjohnsonannualreport capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousands shares amount balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocktherepurchase programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbe availableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailable cashandaccesstothecapitalmarketsasofjanuarybillionhasbeenrepurchasedundertheprogram onjulythecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockthissharerepurchase programwascompletedonapril accumulated comprehensive income componentsofothercomprehensiveincomelossconsistofthefollowing gain total gain loss accumulated foreign loss employee currency benefit derivatives comprehensive dollarsinmillions translation securities plans hedges incomeloss december netchanges december netchanges january netchanges january amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome johnsonjohnsonannualreportdetailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditional details gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthe hedgedtransactionseenoteforadditionaldetails international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyears orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulated othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighlyinflationary economiesthetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperatingresults arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninandrespectively earnings per share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended januaryjanuaryanddecember inmillionsexceptpershareamounts basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod convertibledebtshares adjustedaveragesharesoutstandingdiluted dilutednetearningspershare thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelated reductionininterestexpenseofmillionaftertaxforyearandmillionforyearsand thedilutednetearningspersharecalculationforandincludedallsharesrelatedtostockoptionsas theexercisepriceofalloptionswaslessthantheaveragemarketvalueofthecompanysstock rental expense lease commitments rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases wereapproximatelymillionmillionandmillioninandrespectively johnsonjohnsonannualreport theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatjanuaryare dollarsinmillions total commitmentsundercapitalleasesarenotsignificant common stock stock option plans stock compensation agreements atjanuarythecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontractsunder thecompanyslongtermincentiveplanandthelongtermincentiveplanthelongtermincentive planexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthelong termincentiveplanunderthelongtermincentiveplanthecompanymayissueuptomillionsharesof commonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentiveplan subsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendof thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementfor sharebasedcompensationcostswasmillionmillionandmillionforand respectivelyanadditionaltaxbenefitofmillionwasrecognizedinduetotheadoptionofanewaccounting standardforthereportingofadditionaltaxbenefitsonsharebasedcompensationasdescribedinnotethetotal unrecognizedcompensationcostwasmillionmillionandmillionforandrespectively theweightedaverageperiodforthiscosttoberecognizedwasyearsyearsandyearsfor andrespectivelysharebasedcompensationcostscapitalizedaspartofinventorywereinsignificantinallperiods thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthroughout theyearforthenumberofsharesusedtosettleemployeebenefitequityissuances stockoptions stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforgrantsexpectedvolatilityrepresentsablendedrateof yeardailyhistoricalaveragevolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoneytraded johnsonjohnsonoptionswithalifeofyearsforandgrantsexpectedvolatilityrepresentsablendedrate ofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoney tradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodeterminetheexpectedlife oftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythefair valuewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyears expecteddividendyield johnsonjohnsonannualreportasummaryofoptionactivityundertheplanasofjanuaryjanuaryanddecemberand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weighted value outstanding average dollarsin sharesinthousands shares exerciseprice millions sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatjanuary sharesinthousands outstanding exercisable average average average exercise exercise exercisepricerange options life price options price averagecontractualliferemaininginyears stockoptionsoutstandingatjanuaryanddecemberwereandanaveragelifeofyearsand andanaveragelifeofyearsrespectivelystockoptionsexercisableatjanuaryanddecember wereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunits thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiodof threeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnoperationalsales adjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedatthe endofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgranted johnsonjohnsonannualreport asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofjanuaryis presentedbelow outstanding outstanding restricted performance sharesinthousands shareunits shareunits sharesatdecember granted issued canceledforfeited sharesatdecember granted issued canceledforfeited sharesatjanuary granted issued canceledforfeited sharesatjanuary theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunits issuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandinand calculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninandrespectively segments business geographic areas salestocustomers dollarsinmillions consumer unitedstates international total pharmaceutical unitedstates international total medicaldevices unitedstates international total worldwidetotal johnsonjohnsonannualreportincomebeforetax identifiableassets dollarsinmillions consumer pharmaceutical medicaldevices total lessexpensenotallocatedtosegments generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumer pharmaceutical medicaldevices segmentstotal generalcorporate worldwidetotal salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinthecompanyhadtwowholesalersdistributingproductsforallthreesegments thatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinandthecompany hadonewholesalerdistributingproductsforallthreesegmentsthatrepresentedapproximatelyand respectivelyofthetotalconsolidatedrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecurities includesnetlitigationexpenseofmillionandarestructuringrelatedchargeofmillioninthemedicaldevicessegment thepharmaceuticalsegmentincludesapositiveadjustmentofbilliontopreviousreserveestimatesaninprocessresearchand developmentexpenseofmillionandgainsfromthedivestituresofthecontrolledsubstancerawmaterialandactive pharmaceuticalingredientapibusinessandcertainanestheticproductsineurope themedicaldevicessegmentincludesarestructuringrelatedchargeofmillionanintangibleassetwritedownofmillion relatedtoacclarentsynthesintegrationcostsofmillionandmillionexpenseforthecostassociatedwiththedepuyasr tmhipprogramincludesmillionofinprocessresearchanddevelopmentexpensecomprisedofmillionandmillion inthepharmaceuticalandmedicaldevicessegmentsrespectivelyincludesnetlitigationexpenseofmillioncomprisedof millioninthepharmaceuticalsegmentandmillioninthemedicaldevicessegmentwhichincludedthegainfromthe litigationsettlementagreementwithguidantformillionthemedicaldevicessegmentincludesagainofbillionfromthe divestitureofthecordisbusinessthepharmaceuticalsegmentincludesagainofmillionfromtheusdivestitureof nucyntaandapositiveadjustmentofbilliontopreviousreserveestimatesincludingmanagedmedicaidrebatesthe consumersegmentincludesagainofmillionfromthedivestitureofsplendabrand johnsonjohnsonannualreport includesnetlitigationexpenseofmillioncomprisedofmillionmillionandmillioninthemedicaldevices pharmaceuticalandconsumersegmentsrespectivelyincludesmillionofinprocessresearchanddevelopmentexpense comprisedofmillionandmillioninthepharmaceuticalandmedicaldevicessegmentsrespectivelythemedicaldevices segmentincludesanetgainofmillionfromthedivestitureoftheorthoclinicaldiagnosticsbusinesssynthesintegration costsofmillionandmillionexpenseforthecostassociatedwiththedepuyasrtmhipprogramthepharmaceutical segmentincludesanadditionalyearofthebrandedprescriptiondrugfeeofmillionandapositiveadjustmentofbillionto previousreserveestimates longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyand intangibleassetsandgoodwillnetforandofandrespectively selected quarterly financial data unaudited selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare first second third fourth first second third fourth data quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomers consumer pharmaceutical medicaldevices totalsales grossprofit earningsbeforeprovisionfortaxeson income netearnings basicnetearningspershare dilutednetearningspershare thefirstquarterhasbeenrecasttoreflecttheadoptionofasuseenotetotheconsolidatedfinancialstatementsfor moredetailsthefirstquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnet litigationexpenseofmillionaftertaxmillionbeforetax thesecondquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnetlitigation expenseofmillionaftertaxmillionbeforetax thethirdquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnetlitigationexpense ofmillionaftertaxmillionbeforetax thefourthquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnetlitigation expenseofmillionaftertaxmillionbeforetax thefirstquarterofincludesanetlitigationgainofmillionaftertaxmillionbeforetaxandmillionaftertax millionbeforetaxforcostsassociatedwiththedepuyasrtmhipprogram thesecondquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetax thethirdquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetax thefourthquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxmillionaftertax millionbeforetaxfromimpairmentofinprocessresearchanddevelopmentandsynthesintegrationcostsofmillionafter taxmillionbeforetaxadditionallythefourthquarterofincludesthegainonthecordisdivestiture johnsonjohnsonannualreport business combinations divestitures certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincluded inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedvogueinternationalllcaprivatelyheldcompanyfocusedonthemarketing developmentanddistributionofsaloninfluencedandnatureinspiredhaircareandotherpersonalproductsneuwave medicalincaprivatelyheldmedicaldevicecompanythatmanufacturesandmarketsminimallyinvasivesofttissue microwaveablationsystemsneostratacompanyincagloballeaderindermocosmeticsandtheglobalrightsforthe commercializationofrhinocortallergysprayoutsidetheunitedstates theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thenetpurchasepriceforvogueinternationalllcofbillionwasprimarilyrecordedasamortizableintangibleassets forbillionandgoodwillforbilliontheweightedaveragelifeforthebillionoftotalamortizableintangiblesis approximatelyyearsthetrademarkassetvaluesweredeterminedtohavedefinitelivesrangingfromtoyears withthemajoritybeingyearsthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness acquisitionandisexpectedtobedeductiblefortaxpurposestheassetsacquiredwererecordedintheconsumer segment duringthefiscalthirdquarterofthecompanyannouncedadefinitiveagreementtoacquireabbottmedicaloptics amoawhollyownedsubsidiaryofabbottlaboratoriesforbillionincashtheacquisitionwillinclude ophthalmicproductsrelatedtocataractsurgerylaserrefractivesurgeryandconsumereyehealththetransactionclosed onfebruarythepurchasepriceallocationisinprogressandisexpectedtoresultinanallocationofsignificant valuetotheamortizableintangibleassetswithanyresidualrecordedasgoodwill onjanuarysubsequenttoyearendthecompanyannouncedadefinitivetransactionagreementunderwhich thecompanywilllaunchanallcashtenderofferinswitzerlandtoacquirealloftheoutstandingsharesofactelionltdfor persharepayableinusdollarsforapproximatelybillionaspartofthetransactionimmediatelypriortothe completionoftheacquisitionactelionwillspinoutitsdrugdiscoveryoperationsandearlystageclinicaldevelopment assetsintoanewlycreatedswissbiopharmaceuticalcompanyrdnewcothesharesofrdnewcowhichwillbe listedonthesixswissexchangesixwillbedistributedtoactelionsshareholdersasastockdividenduponclosingof thetenderthecompanywillinitiallyholdofthesharesofrdnewcoandhaverightstoanadditionalofrd newcoequitythroughaconvertiblenoteactelionhasestablishedaleadingfranchiseofdifferentiatedinnovative productsforpulmonaryarterialhypertensionpahthatishighlycomplementarytotheexistingportfolioofthecompany theadditionofactelionsspecialtyinmarketmedicinesandlatestageproductsisconsistentwiththecompanysefforts togrowinattractiveandcomplementarytherapeuticareasandservepatientswithseriousillnessesandsignificantunmet medicalneedtheclosingissubjecttothedemergerantitrustclearanceandothercustomaryclosingconditions onfebruarysubsequenttoyearendthecompanyreceivedabindingofferfromintegralifesciencesholdings corporationtopurchasethecodmanneurosurgerybusinessforapproximatelybillion subsequenttoyearendthecompanyannounceditisengaginginaprocesstoevaluatepotentialstrategicoptionsfor thejohnsonjohnsondiabetescarecompaniesspecificallylifescanincanimascorporationandcalibramedical incstrategicoptionsmayincludetheformationofoperatingpartnershipsjointventuresorstrategicalliancesasaleof thebusinessesorotheralternativeseitherseparatelyortogetheralloptionswillbeevaluatedtodeterminethebest opportunitytodrivefuturegrowthandmaximizeshareholdervaluetherecanbenoassurancethatthisprocesswillresult inanytransactionorotherstrategicalternativeofanykindthereforetherewerenoassetsheldforsaleasofjanuary relatedtotheannouncement certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthe assumedliabilitiesprimarilyrepresentthefairvalueofthecontingentconsiderationofmilliontheseacquisitions wereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincludedinthe financialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedxolimitedaprivatelyheldbiopharmaceuticalcompanydevelopingananti thrombinantibodyandnoviratherapeuticsincaprivatelyheldclinicalstagebiopharmaceuticalcompanydeveloping innovativetherapiesforcurativetreatmentofchronichepatitisbvirusinfection johnsonjohnsonannualreport theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdprimarilyassociatedwiththeacquisitionsofxolimitedandnovira therapeuticsincthevalueoftheiprdwascalculatedusingcashflowprojectionsdiscountedfortheinherentriskin theprojects theiprdrelatedtotheacquisitionofxolimitedofmillionisassociatedwitharecombinanthumanantibody developedtomimictheactivityofahumanantibodywhichappearstoproduceananticoagulatedstatewithout predispositiontobleedingaprobabilityofsuccessfactorofwasusedtoreflectinherentclinicalandregulatory riskthediscountrateappliedwas theiprdrelatedtotheacquisitionofnoviratherapeuticsincofmillionisassociatedwithitsleadcandidatenvr whichisaninvestigationalsmallmoleculedirectactingantiviralfororaladministrationinpatientswithhbvthat inhibitsthehbvcoreorcapsidproteinaprobabilityofsuccessfactorofwasusedtoreflectinherentclinicaland regulatoryriskthediscountrateappliedwas certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincluded inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedcovagenagaprivatelyheldbiopharmaceuticalcompanyspecializinginthe developmentofmultispecificproteintherapeuticsthroughthefynomabtechnologyplatformaliosbiopharmainca privatelyheldclinicalstagebiopharmaceuticalcompanyfocusedondevelopingtherapiesforviraldiseasesandthe orsltmelectrolytereadytodrinkbrandfromjagdaleindustriesltdtheexcessofpurchasepriceovertheestimatedfair valueoftangibleassetsacquiredamountedtomillionandhasbeenassignedtoidentifiableintangibleassetswith anyresidualrecordedtogoodwillofthisamountapproximatelymillionhasbeenidentifiedasthevalueofiprd associatedwiththeacquisitionsofcovagenagandaliosbiopharmaincthevalueoftheiprdwascalculatedusing cashflowprojectionsdiscountedfortheinherentriskintheprojects theiprdrelatedtotheacquisitionofaliosbiopharmaincofmillionisassociatedwithaliosleadcompound alanorallyadministeredantiviraltherapyfortreatmentofinfantswithrespiratorysyncytialvirusrsvaprobability ofsuccessfactorofwasusedtoreflectinherentclinicalandregulatoryriskthediscountrateappliedwas theiprdrelatedtotheacquisitionofcovagenagofmillionisassociatedwithcovagensleadcompound covacurrentlyinphasebstudyforpsoriasisandholdingpotentialasatreatmentforabroadrangeof inflammatorydiseasesincludingrheumatoidarthritisaprobabilityofsuccessfactorofwasusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwasduringthecompanyrecordedachargeforthe impairmentoftheiprdrelatedtotheacquisitionofcovagenag inthecompanycompletedtheacquisitionofsynthesincforapurchasepriceofbillionincashandstock inconnectionwiththeacquisitionofsynthesincthecompanyenteredintotwoacceleratedsharerepurchaseasr agreementsinthecompanysettledtheremainingliabilitiesundertheasragreementswhilethecompany believesthatthetransactionsundereachasragreementandaseriesofrelatedinternaltransactionswereconsummated inataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternalrevenueservicecouldassert oneormorecontrarypositionstochallengethetransactionsfromataxperspectiveifchallengedanamountuptothe totalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableustaxatapproximatelythe statutoryratetothecompanyplusinterest supplementalproformainformationforandinaccordancewithusgaapstandardsrelatedto businesscombinationsandgoodwillandotherintangibleassetsisnotprovidedastheimpactoftheaforementioned acquisitionsdidnothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition duringthecompanydivestituresincludedthecontrolledsubstancerawmaterialandactivepharmaceutical ingredientapibusinesscertainanestheticproductsineuropeandcertainnonstrategicconsumerbrandsinthe pretaxgainsonthedivestitureswereapproximatelybillion duringthecompanydivestituresincludedthecordisbusinesstocardinalhealththesplendabrandto heartlandfoodproductsgroupandtheuslicenserightstonucyntatapentadolnucyntaertapentadol extendedreleasetabletsandnucyntatapentadoloralsolutioninthepretaxgainsonthedivestitureswere approximatelybillion duringthecompanydivestituresincludedtheorthoclinicaldiagnosticsbusinesstothecarlylegrouptheky brandtoreckittbenckisergroupplcintheusandcertainothermarketsandthebenecolbrandtoraisioplc johnsonjohnsonannualreportinthepretaxgainsonthedivestitureswereapproximatelybillionthecompanycompletedthedivestitureof itsorthoclinicaldiagnosticsbusinesstothecarlylegroupforapproximatelybillionandthecompanyrecordeda pretaxgainofapproximatelybillionorthoclinicaldiagnosticsresultsareincludedinthecompanysmedical devicessegment legal proceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactors includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscovery hasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiesthereare significantfactsindisputeortherearenumerouspartiesinvolved inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod productliability johnsonjohnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationthe companyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithascbasedon currentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesanestimateofthelegal defensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonablyestimatedforcertain ofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociatedwithsettlements damagesandotherlossestotheextentadverseverdictshavebeenrenderedagainstthecompanythecompanydoes notrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedproductliabilityaccruals canrepresentprojectedproductliabilityforthousandsofclaimsaroundtheworldeachindifferentlitigationenvironments andwithdifferentfactpatternschangestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes available themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesrisperdalxareltoandjohnsonsbaby powderasofjanuaryintheustherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuits regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswith respecttorisperdalwithrespecttoxareltoandwithrespecttojohnsonsbabypowder inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhas alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliaireland johnsonjohnsonannualreport germanyanditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyers representingasrhipsystemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunited stateswhohadsurgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustthissettlement coveredapproximatelypatientsinfebruarydepuyreachedanadditionalagreementwhicheffectively extendstheexistingsettlementprogramtoasrhippatientswhohadrevisionsurgeriesafteraugustandprior tofebruarythissecondagreementisestimatedtocoverapproximatelyadditionalpatientstheestimated costoftheseagreementsiscoveredbyexistingaccrualsthissettlementprogramisexpectedtobringtoaclose significantasrhiplitigationactivityintheunitedstateshowevermanylawsuitsintheunitedstateswillremainandthe settlementprogramdoesnotaddresslitigationoutsideoftheunitedstatesinaustraliaasettlementwasreachedwith representativesofaclassactionlawsuitpendinginthefederalcourtofnewsouthwalesthatresolvestheclaimsofthe majorityofasrhippatientsinthatcountrythecompanycontinuestoreceiveinformationwithrespecttopotentialcosts associatedwiththisrecallonaworldwidebasisthecompanyhasestablishedaccrualsforthecostsassociatedwiththe depuyasrhipprogramandrelatedproductliabilitylitigationchangestotheseaccrualsmayberequiredinthefuture asadditionalinformationbecomesavailable claimsforpersonalinjuryhavealsobeenmadeagainstdepuyandjohnsonjohnsonrelatingtothepinnacle acetabularcupsystemusedinhipreplacementsurgerythenumberofpendingproductliabilitylawsuitscontinuesto increaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunited statesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledincountriesoutsideoftheunited statesprimarilyintheunitedkingdomthecompanyhasestablishedanaccrualfordefensecostsinconnectionwith productliabilitylitigationassociatedwiththepinnacleacetabularcupsystemchangestothisaccrualmaybe requiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicons pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethenumberofpendingproduct liabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcosts andtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwestvirginiainadditionclassactionsand individualpersonalinjurycasesorclaimshavebeencommencedinvariouscountriesoutsideoftheunitedstates includingclaimsandcasesintheunitedkingdomthenetherlandsbelgiumitalyandvenezuelaandclassactionsin israelaustraliaandcanadaseekingdamagesforallegedinjuryresultingfromethiconspelvicmeshdevicesthe companyhasestablishedanaccrualwithrespecttoproductliabilitylitigationassociatedwithethiconspelvicmesh productschangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofrisperdalindicatedforthetreatmentofschizophreniaacutemanicormixedepisodesassociatedwithbipolari disorderandirritabilityassociatedwithautismandrelatedcompoundslawsuitshavebeenprimarilyfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanadathe numberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwith respecttopotentialcostsandtheanticipatednumberofcasesthecompanyhasestablishedanaccrualwithrespectto productliabilitylitigationassociatedwithrisperdalchangestothisaccrualmayberequiredinthefutureas additionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofxareltoanoralanticoagulantthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthe companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcasescases filedinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrict courtfortheeasterndistrictoflouisianainadditioncaseshavebeenfiledinstatecourtsacrosstheunitedstates manyofthesecaseshavebeenconsolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandthereare coordinatedproceedingsindelawarecaliforniaandmissouriclassactionlawsuitsalsohavebeenfiledincanadathe companyhasestablishedanaccrualfordefensecostsinconnectionwithproductliabilitylitigationassociatedwith xareltochangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjohnsonjohnsonconsumerincandjohnsonjohnsonarisingout oftheuseofjohnsonsbabypowderthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthe companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcaseslawsuits havebeenprimarilyfiledinstatecourtsinmissourinewjerseyandcaliforniainadditionafederalmultidistrictlitigation proceedinghasbeencreatedforthislitigationinthedistrictcourtofnewjerseythecompanyhasestablishedan johnsonjohnsonannualreportaccrualfordefensecostsinconnectionwithproductliabilitylitigationassociatedwithjohnsonsbaby powderchangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanys productsinfringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto thesechallengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeof thesemattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts resultinlossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmay resultinanoncashimpairmentchargeforanyassociatedintangibleassetthemostsignificantofthesemattersare describedbelow medicaldevices injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvciintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcis manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringetheirus patentnothepatentrembrandtisseekingmonetaryreliefthecasewastransferredtotheunited statesdistrictcourtforthemiddledistrictoffloridainmaythejuryreturnedaverdictholdingthatneitherofthe accusedlensesinfringesthepatentrembrandtappealedandinaugusttheunitedstatescourtofappeals forthefederalcircuitaffirmedthedistrictcourtsjudgmentrembrandtaskedthedistrictcourttograntitanewtrial basedonallegednewevidenceandinjulythedistrictcourtdeniedrembrandtsmotionrembrandtappealed andthecourtofappealsoverturnedthatrulinginaprilandremandedthecasetothedistrictcourtforanewtrial jjvcismotiontoreconsiderandpetitionforreviewwiththeunitedstatessupremecourtwerebothdeniedanewtrial isscheduledforaugust indecemberthestateofisraelfiledalawsuitinthedistrictcourtintelavivjaffaagainstomrix biopharmaceuticalsincandvariousaffiliatesomrixinthelawsuitthestateclaimedthatanemployeeofagovernment ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe wasagovernmentemployeethestateclaimedthathehadnorighttotransferanyintellectualpropertytoomrixbecause itbelongstothestatethestatesoughtdamagesplusroyaltiesonquixilandevicelproductsoralternatively transferofthepatentstothestatethecasewassettledindecember lifescanfiledapatentinfringementlawsuitagainstunistriptechnologiesllcunistripintheunitedstatesdistrict courtforthedistrictofnorthcarolinainmayallegingthatthemakingandmarketingofunistripsstripsforusein lifescansbloodglucosemonitorsinfringeuspatentnosthepatentandthe patentinaugusttheunitedstatespatentandtrademarkofficeusptodeterminedthatthepatentis invalidinjanuarytheinvaliditydecisionwasupheldonappeallifescanfiledamotionforrehearingwhichwas deniedinjulyunistripbroughtalawsuitagainstlifescanintheunitedstatesdistrictcourtfortheeasterndistrict ofpennsylvaniaallegingantitrustviolationsrelatingtomarketingpracticesforlifescanstrips inmarchmedinolltdmedinolfiledapatentinfringementlawsuitagainstcordiscorporationcordisand johnsonjohnsonintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkallegingthatallofcordiss salesofthecypherandcypherselectstentsmadeintheunitedstatessincewillfullyinfringedfourof medinolspatentsdirectedtothegeometryofarticulatedstentsmedinolisseekingdamagesandattorneysfeesafter trialinjanuarythedistrictcourtdismissedthecasefindingmedinolunreasonablydelayedbringingitsclaimsand medinoldidnotappealthedecisioninseptemberthedistrictcourtdeniedamotionbymedinoltovacatethe judgmentandgrantitanewtrialmedinolsappealofthisdecisionhasbeendismissedmedinolhasfiledapetitionfor reviewwiththeunitedstatessupremecourtcordiswasdivestedinandthecompanyretainedanyliabilitythat mayresultfromthiscase innovembermedideallcmedideafiledapatentinfringementlawsuitagainstdepuyorthopaedicsincinthe unitedstatesdistrictcourtforthenortherndistrictofillinoisalleginginfringementbytheattunekneesystemoftwo patentsrelatingtoposteriorstabilizedkneesystemsspecificallymedideaallegesthatthesofcamtmcontactfeatureof theattuneposteriorstabilizedkneeproductsinfringesthepatentsinsuitmedideaisseekingmonetarydamagesand injunctiverelief johnsonjohnsonannualreport indecemberethiconendosurgeryincandethiconendosurgeryllcnowknownasethiconllcsued covidienincintheusdistrictcourtforthedistrictofmassachusettsseekingadeclarationthatcovidiensuspatent nosandareeitherinvalidornotinfringedbyethicons ensealxlargejawtissuesealerproductensealxtheensealxproductisscheduledtolaunchinthe unitedstatesandeuropeinthefirstquarterof pharmaceutical inaprilmorphosysagagermanbiotechcompanyfiledapatentinfringementlawsuitagainstjanssenbiotech incjbigenmabusincandgenmabascollectivelygenmabintheunitedstatesdistrictcourtforthedistrictof delawareallegingthatjbismanufactureandsaleofdarzalexdaratumumabwillfullyinfringesmorphosysus patentnomorphosysisseekingmoneydamagesjbilicensespatentsandthecommercialrightsto darzalexfromgenmabinjunejbifiledamotiontodismissthelawsuitinnovembermorphosys soughtleavetoaddanotherpatenttothecaseuspatentnoandinfebruarythecourtgrantedthe requesttrialinthecaseiscurrentlyscheduledtocommenceinaugust inaugustsandozltdandhexalagcollectivelysandozfiledalawsuitintheenglishhighcourtagainstgd searlellcapfizercompanyandjanssensciencesirelanducjsiallegingthatsearlessupplementaryprotection certificatespcgbspcwhichisexclusivelylicensedtojsiisinvalidandshouldberevokedjanssencilag limitedsellsprezistadarunavirintheukpursuanttothislicenseinoctobersearleandjsicounterclaimed againstsandozforthreatenedinfringementofthespcbasedonstatementsofitsplanstolaunchgenericdarunavirinthe uktrialofthecasehasbeenscheduledtobegininlateaprilearlymay remicaderelatedcases usproceedings inseptemberjanssenbiotechincjbiandnyulangonemedicalcenternyureceivedanofficeactionfrom theunitedstatespatentandtrademarkofficeusptorejectingtheclaimsinuspatentnorelatingto remicadeinfliximabthepatentinareexaminationproceedinginstitutedbyathirdpartythepatentisco ownedbyjbiandnyuandnyugrantedjbianexclusivelicensetonyusrightsunderthepatentthepatent expiresinseptemberfollowingseveralofficeactionsbythepatentexaminerincludingtwofurtherrejectionsand responsesbyjbitheusptoissuedafurtheractionmaintainingitsrejectionofthepatentjbifiledanoticeof appealtotheusptospatenttrialandappealboardinnovemberthepatenttrialandappealboardissueda decisionupholdingtheexaminersrejectionjbihasfiledanappealtotheuscourtofappealsforthefederalcircuit inaugustcelltrionhealthcarecoltdandcelltrioninctogethercelltrionfiledanapplicationwiththeusfood anddrugadministrationfdaforapprovaltomakeandsellitsowninfliximabbiosimilarinmarchjbifiledalawsuit intheunitedstatesdistrictcourtforthedistrictofmassachusettsagainstcelltrionandhospirahealthcarecorporation hospirawhichhasexclusiveusmarketingrightsforcelltrionsinfliximabbiosimilarseekingamongotherthingsa declaratoryjudgmentthattheirbiosimilarproductinfringesorpotentiallyinfringesseveraljbipatentsincludingthe patentanduspatentnothepatentinaugustthedistrictcourtgrantedbothcelltrions andhospirasmotionsforsummaryjudgmentofinvalidityofthepatentjbihasappealedthosedecisionstotheus courtofappealsforthefederalcircuitthiscaseandtheappealofthereexaminationofthepatenthavebeen designatedcompanioncasesandwillbeheardbythesamepanelofjudgesinthefederalcircuit injunejbifiledtwoadditionalpatentinfringementlawsuitsassertingthepatentoneagainstcelltrioninthe unitedstatesdistrictcourtforthedistrictofmassachusettsandtheotheragainsthyclonelaboratoriesincthe manufacturerofthecellculturemediathatcelltrionusestomakeitsbiosimilarproductintheunitedstatesdistrictcourt forthedistrictofutahalthoughthepatentisalreadyassertedintheexistinglawsuitagainstcelltriontheadditional lawsuitexpandstheclaimstoincludeanyuseofthecellculturemediamadeintheunitedstatestomanufacture celltrionsbiosimilarthisadditionallawsuitagainstcelltrionhasbeenconsolidatedwiththeexistinglawsuitdiscussed abovehospirahasmovedtodismissallcountsofthelawsuitrelatedtothepatentastoitcelltrionhasmovedto dismissallcountsofthelawsuitrelatedtothepatentwithoutprejudiceforfailuretojoinallthecoownersofthe patentasplaintiffsthetrialhasbeenpostponedpendingresolutionofthesemotions thefdaapprovedcelltrionsinfliximabbiosimilarforsaleintheunitedstatesinaprilandthedayperiodfor noticeoflaunchofabiosimilarproductunderthebiologicspricecompetitionandinnovationacthaspassed johnsonjohnsonannualreporthospirasparentcompanypfizerincbeganshipmentofcelltrionsinfliximabbiosimilartowholesalersintheunited statesinlatenovemberintroductiontotheusmarketofthebiosimilarwillresultinareductioninussalesof remicade canadianproceedings inmarchhospirafiledanimpeachmentproceedingagainstthekennedyinstituteofrheumatologykennedy challengingthevalidityofacanadianpatentrelatedtoremicadeafeldmanpatentwhichisexclusivelylicensedto jbiinoctoberkennedyalongwithjbijanssenincjanssenandcilaggmbhinternationalbothaffiliatesofjbi filedacounterclaimforinfringementagainstcelltrionandhospirathecounterclaimallegesthattheproductsdescribedin celltrionsandhospirasmarketingapplicationstohealthcanadafortheirsubsequententrybiologicssebto remicadewouldinfringethefeldmanpatentsownedbykennedyatrialinthispatentactionconcludedinoctober andclosingargumentstookplaceinjanuarythepartiesareawaitingadecision injanuaryhealthcanadaapprovedcelltrionssebtoremicadeallowingcelltriontomarketitsinfliximab biosimilarincanadaregardlessofthependingpatentactioninjunehealthcanadaapprovedhospirassebto remicadeinjulyjanssenfiledalawsuittocompelthecanadianministerofhealthtowithdrawthenoticeof complianceforhospirassebbecausehospiradidnotserveanoticeofallegationonjanssentoaddressthepatent listedbyjanssenonthepatentregisterinmarchthepartiesenteredintoasettlementagreementwherebyhealth canadaagreedtoaconsentjudgmentsettingasidehospirasnoticeofcompliancesubjecttohealthcanadasappeal whichwasfiledinjuneneverthelesshospirabeganmarketinganinfliximabbiosimilarasadistributorunder celltrionsnoticeofcomplianceinoctobertheappealscourtreversedtheconsentjudgmentjanssenhasfiled anapplicationforleavetoappealwiththesupremecourtofcanadahospiracontinuestomarketandsellcelltrions infliximabbiosimilarincanada incanadaiftheremicadepatentdiscussedaboveisfoundtobeinvalidfollowingallappealsitcouldnotberelied upontopreventthefurtherintroductionofinfliximabbiosimilarspriortotheaugustexpirydateofthepatent litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledabbreviatednewdrugapplications andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgeneric formsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscovering thoseproductstheseandastypicallyincludeallegationsofnoninfringementinvalidityandunenforceabilityofthe applicablepatentsintheeventthesubsidiariesarenotsuccessfulintheseactionsorthestatutorymonthstaysofthe andasexpirebeforetheunitedstatesdistrictcourtrulingsareobtainedthethirdpartycompaniesinvolvedwillhavethe abilityuponapprovalofthefdatointroducegenericversionsoftheproductsatissuetothemarketresultinginthe potentialforsubstantialmarketshareandrevenuelossesforthoseproductsandwhichmayresultinanoncash impairmentchargeinanyassociatedintangibleassetinadditionfromtimetotimesubsidiariesmaysettletheseactions andsuchsettlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarketpriortothe expirationoftherelevantpatentstheinterpartesreviewiprprocesswiththeunitedstatespatentandtrademark officeusptocreatedundertheamericainventsactisalsobeingusedbygenericcompaniesinconjunction withtheseandasandlawsuitstochallengepatentsheldbythecompanyssubsidiaries concerta indecemberjanssenincandalzacorporationfiledanoticeofapplicationagainstactavispharmacompany actavisinresponsetoactavisnoticeofallegationseekingapprovaltomarketagenericversionofconcertabefore theexpirationofcanadianpatentnothepatentindecemberthecanadianfederalcourt allowedtheapplicationandissuedanorderpreventingactavisfromobtainingmarketingapprovalanoticeof complianceforitsgenericversionofconcertauntiltheexpirationofthepatentactavisdidnotcommencean appealpriortothedeadlinefordoingsoandthusispreventedfromobtaininganoticeofcomplianceforageneric versionofconcertauntiltheexpirationofthepatent inoctoberalzacorporationandjanssenpharmaceuticalsincfiledapatentinfringementlawsuitintheus districtcourtforthedistrictofdelawareagainstamnealpharmaceuticalsofnewyorkllcandamnealpharmaceuticals llcinresponsetoamnealsandaseekingapprovaltomarketagenericversionofconcertabeforetheexpirationof unitedstatespatentnosandinnovemberamnealfiledamotionforjudgmentonthe pleadingsarguingthatcertainclaimsofthepatentsareinvalidandothersarenotinfringedjanssenhasopposedthe motion johnsonjohnsonannualreport zytiga injuneandjulyjanssenbiotechincjbireceivednoticesofparagraphivcertificationfromseveralcompanies advisingoftheirrespectiveandasseekingapprovalforagenericversionofzytigabeforetheexpirationofoneor morepatentsrelatingtozytigainjulyjbijanssenoncologyincjanssenoncologyandjanssenresearch developmentllccollectivelyjanssenandbtginternationalltdbtgfiledapatentinfringementlawsuitintheunited statesdistrictcourtforthedistrictofnewjerseyagainstseveralgenericandaapplicantsandcertainoftheiraffiliates andorsuppliersinresponsetotheirrespectiveandasseekingapprovaltomarketagenericversionofzytigabefore theexpirationofunitedstatespatentnosthepatentandorthepatentthegeneric companiesincludeactavislaboratoriesflincactavisamnealpharmaceuticalsllcandamnealpharmaceuticalsof newyorkllccollectivelyamnealapotexincandapotexcorpcollectivelyapotexcitronpharmallccitron drreddyslaboratoriesltdanddrreddyslaboratoriesinccollectivelydrreddysmylanpharmaceuticalsinc andmylaninccollectivelymylanparpharmaceuticalsincandparpharmaceuticalcompaniesinccollectivelypar sunpharmaceuticalindustriesltdandsunpharmaceuticalsindustriesinccollectivelysuntevapharmaceuticals usainctevawockhardtbioagwockhardtusallcandwockhardtltdcollectivelywockhardtwestward pharmaceuticalcorpwestwardandhikmapharmaceuticalsllchikmathecourtenteredastayofthelawsuit againstparandcitronaseachagreedtobeboundbythedecisionagainsttheotherdefendantsintheactionthe patentexpiredindecemberandthustheinfringementactionsconcernonlythepatentinfebruarythe courtsetatrialdateofoctober inaugustjanssenandbtgfiledanadditionaljurisdictionalprotectivelawsuitagainstthemylandefendantsinthe unitedstatesdistrictcourtforthenortherndistrictofwestvirginiawhichhasbeenstayed inaugustjanssenreceivedanoticeofparagraphivcertificationfromheterousainctheusregulatoryagent forheterolabslimitedunitvadivisionofheterolabslimitedcollectivelyheteroadvisingofheterosandaseeking approvalforagenericversionofzytigabeforeexpirationofthepatentinseptemberjanssenandbtg filedanamendedcomplaintinthenewjerseylawsuittoaddallegedinfringementofthepatentbyhetero inmarchjanssenfiledamotioninthenewjerseylawsuittocorrectinventorshipofthepatenttoaddan inventorandifgrantedforleavetoamendthecomplaintaccordinglyinjanuarythecourtgrantedjanssens motionandjanssenfiledasecondamendedcomplaintaddingbtgasacoownerofthepatentandacoplaintiff regardingthepatentinfringementclaims inmarchjanssenreceivedanoticefromamerigenpharmaceuticalslimitedamerigenadvisingofamerigens andaseekingapprovalforagenericversionofzytigabeforeexpirationofthepatentinresponsejanssenand btgfiledaseparatepatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainst amerigeninmay inmayjanssenreceivedanoticeofparagraphivcertificationfromglenmarkpharmaceuticalsinconbehalfof glenmarkpharmaceuticalssaawhollyownedsubsidiaryofglenmarkpharmaceuticalsltdcollectivelyglenmark advisingofglenmarksandaseekingapprovalforagenericversionofzytigabeforeexpirationofthepatentin responseinjunejanssenandbtgfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstglenmarkthepartieshavestipulatedtoadismissalofglenmarkpharmaceuticalsltd thefilingoftheabovereferencedlawsuitstriggeredastayuntiloctoberduringwhichtimethefdawillnotgrant finalapprovalofthegenericsandasunlessthereisanearlierdistrictcourtdecisionfindingthepatentsinsuitinvalidor notinfringed ineachoftheabovelawsuitsjanssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversions ofzytigabeforetheexpirationoftherelevantpatents indecemberamerigenfiledapetitionforaninterpartesreviewintheusptoseekingtoinvalidatethepatent inmaytheusptograntedtheinterpartesreviewandadecisionastothevalidityofthepatentisexpected bymayinjuneargentumpharmaceuticalsllcandmylanpharmaceuticalsincfiledpetitionsforinterpartes reviewintheusptoseekingtoinvalidatethepatentandmovedtojointheinterpartesreviewfiledbyamerigenthe usptoinstitutedargentumspetitionandgrantedargentumsmotionforjoinderandinjanuarygrantedmylans petitionforinterpartesreviewbutdeniedmylansmotionforjoinderinaugustwockhardtbioagfiledapetition forinterpartesreviewintheusptoseekingtoinvalidatethepatentwhichtheusptograntedinjanuaryin februaryactavisamnealdrreddyssuntevawestwardandhikmafiledajointpetitionforinterpartesreview intheusptoseekingtoinvalidatethepatentandmovedtojointheinterpartesreviewfiledbymylan johnsonjohnsonannualreportcomplera inaugustandseptemberjanssenpharmaceuticanvandjanssensciencesirelanduccollectivelyjanssenand gileadsciencesincandgileadsciencesirelanduccollectivelygileadfiledpatentinfringementlawsuitsintheunited statesdistrictcourtsforthedistrictofdelawareandthedistrictofwestvirginiarespectivelyagainstmylanincand mylanpharmaceuticalsinccollectivelymylaninresponsetomylansandaseekingapprovaltomarketageneric versionofcomplerabeforetheexpirationofunitedstatespatentnosthepatentthe patentandthepatent inthewestvirginiaactioninseptembermylanfiledananswerandcounterclaimsassertinginvalidityandnon infringementofthepatentpatentandpatentaswellasunitedstatespatentnothe patentinmarchthedistrictofwestvirginiacourtstayedthelawsuitandscheduledaconditionaltrialdatein februaryinaccordancewiththescheduleinthefirstfileddelawarelawsuitdescribedbelow inthedelawareactioninjanuaryandmarchjanssenandgileadamendedtheircomplainttoaddclaimsforpatent infringementwithrespecttothepatentandunitedstatespatentnosthepatentthe patentthepatentandthepatentmylanfiledamotiontodismissthesuitfor lackofpersonaljurisdictionandamotiontodismissstrikeorsevertheinfringementclaimsregardingtheand patentsinseptemberthedelawaredistrictcourtdeniedbothofmylansmotionsatrialinthedelaware actionhasbeenscheduledforfebruary ineachoftheselawsuitsjanssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof complerabeforetheexpirationoftherelevantpatents xarelto anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofxareltoinoctober janssenpharmaceuticalsincjpiandbayerpharmaagandbayerintellectualpropertygmbhcollectively bayerfiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstaurobindo pharmalimitedaurobindopharmausaincbreckenridgepharmaceuticalincmicrolabsusaincandmicrolabs ltdcollectivelymicromylanpharmaceuticalsincmylanincmylanprinstonpharmaceuticalincsigmapharm laboratoriesllctorrentpharmaceuticalslimitedandtorrentpharmaincinresponsetothosepartiesrespective andasseekingapprovaltomarketgenericversionsofxareltobeforetheexpirationofbayersunitedstatespatent nosthepatentthepatentandthepatentrelatingtoxarelto jpiistheexclusivelicenseeoftheassertedpatents innovembermylanmovedtodismisstheactionindecemberjpibayerandmylanstipulatedandagreedto dismisstheclaimsagainstmylanandsuspendfurtherbriefingandargumentonmylansmotiontodismisspending appealsrelatingtopersonaljurisdictionovermylanpharmaceuticalsincinthedistrictofdelawareinfebruarya similarpatentinfringementactionbyjpiandbayeragainstinvagenpharmaceuticalsincinvageninresponseto invagensnoticeofparagraphivcertificationadvisingofitsandaseekingfdaapprovalforagenericxarelto productbeforeexpirationoftherelevantpatentswasconsolidatedwiththeoriginalcasethedistrictcourthassetatrial dateofmarch inapriljpiandbayerfiledaseparatepatentinfringementactioninthedistrictofdelawareagainstmicroin responsetotheirnoticeofparagraphivcertificationadvisingoftheirandaseekingfdaapprovalforageneric xareltoproductbeforeexpirationoftheandpatentsinmaythisactionwasconsolidatedwiththe originalaction injulyjpiandbayerfiledaseparatepatentinfringementactioninthedistrictofdelawareagainstbreckenridge pharmaceuticalincinresponsetoitsnoticeofparagraphivcertificationadvisingofitsandaseekingfdaapprovalfor agenericxareltoproductbeforeexpirationoftheandpatentsthisactionhasbeenconsolidatedwiththe originalaction ineachoftheselawsuitsjpiisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof xareltobeforetheexpirationoftherelevantpatents inoctobermylanfiledpetitionsforinterpartesreviewintheusptoseekingtoinvalidatetheand patents johnsonjohnsonannualreport governmentproceedings likeothercompaniesinthepharmaceuticalandmedicaldevicesindustriesjohnsonjohnsonandcertainofits subsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstatesand othercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemostsignificant litigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethatcriminal chargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompaniesaredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct becauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesalepriceawpforthedrugs atissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsmanyofthesecases bothfederalactionsandstateactionsremovedtofederalcourtwereconsolidatedforpretrialpurposesinamultidistrict litigationmdlintheunitedstatesdistrictcourtforthedistrictofmassachusettstheplaintiffsinthesecasesincluded threeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseofthedrugsatissuebasedonawp andstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissuebasedonawpinjuneaftera trialonthemeritsthemdlcourtdismissedtheclaimsoftwooftheplaintiffclassesagainstthejjawpdefendantsin marchthecourtdismissedtheclaimsofthethirdclassagainstthejjawpdefendantswithoutprejudice awpcasesbroughtbyvariousattorneysgeneralhaveproceededtotrialagainstothermanufacturersseveralstate casesagainstcertainjohnsonjohnsonsubsidiarieshavebeensettledincludingthecaseinwisconsinwhichsettledin februarycasesarestillpendinginillinoisnewjerseyandutahthecasesinillinoisandnewjerseyhavenotyet proceededtotrialinutahtheclaimsbroughtbytheattorneygeneralweredismissedbythecourtinbutthestate mayappealthedismissalaftertheconclusionofsimilarpendingmattersagainstotherdefendantsintheawpcase againstthejjawpdefendantsbroughtbythecommonwealthofpennsylvaniafollowingatrialinthe pennsylvaniacommonwealthcourtfoundinfavorofthecommonwealthwithregardtocertainofitsclaimsunderthe pennsylvaniaunfairtradepracticesandconsumerprotectionlawandinfavorofthejjawpdefendantsonthe commonwealthsremainingclaimsfollowinganappealtothepennsylvaniasupremecourtthatvacatedthatjudgment thecommonwealthcourtenteredasubsequentjudgmentinfavorofthejjawpdefendantsonallclaimsthat subsequentjudgmenthasbeenupheldbythepennsylvaniasupremecourtinasuccessiveappeal mcneilconsumerhealthcare startinginjunemcneilconsumerhealthcaredivisionofmcneilppcincnowjohnsonjohnsonconsumer incmcneilconsumerhealthcaredivisionmcneilconsumerhealthcareandcertainaffiliatesincludingjohnson johnsonthecompaniesreceivedgrandjurysubpoenasfromtheunitedstatesattorneysofficefortheeasterndistrict ofpennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvariousproductsofmcneilconsumerhealthcareand thefdainspectionsofthefortwashingtonpennsylvaniaandlancasterpennsylvaniamanufacturingfacilitiesaswellas certaindocumentsrelatingtorecallsofasmallnumberofproductsofothersubsidiariesinadditioninfebruarythe governmentservedmcneilppcincnowjohnsonjohnsonconsumerincjjciwithacivilinvestigativedemand seekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationofthefederalfalseclaimsactinmarch mcneilppcincnowjjcienteredaguiltypleaintheunitedstatesdistrictcourtfortheeasterndistrictof pennsylvaniatoamisdemeanorviolationoftheusfooddrugandcosmeticactmcneilppcincnowjjciagreed topayamillionfineandamillionforfeituretoresolvethematter thecompanieshavealsoreceivedcivilinvestigativedemandsfrommultiplestateattorneysgeneralofficesbroadly relatingtothemcneilrecallissuesthecompaniescontinuetocooperatewiththeseinquirieswhicharebeing coordinatedthroughamultistatecoalitionifaresolutioncannotbereachedwiththismultistatecoalitionitispossible thatindividualstateattorneysgeneralofficesmayfilecivilmonetaryclaimsagainstthecompanies injanuarytheoregonattorneygeneralfiledacivilcomplaintagainstjohnsonjohnsonmcneilppcincnow jjciandmcneilhealthcarellcinstatecourtallegingcivilviolationsoftheoregonunlawfultradepracticesactrelating toanearlierrecallofamcneilotcproductinnovemberthestatecourtgrantedamotionbythecompaniesto dismissoregonscomplaintinitsentiretywithprejudiceinnovemberthestatecourtofappealsreversedthetrial courtandreinstatedoregonsconsumerprotectionclaimsinfebruarytheoregonsupremecourtdeniedthe companiespetitionforreviewandthecasewassentbacktothetrialcourt johnsonjohnsonannualreportopioidslitigation asdescribedbelowjohnsonjohnsonjjandjanssenpharmaceuticalsincjpialongwithotherpharmaceutical companieshavebeennamedinfourlawsuitsallegingclaimsrelatedtomarketingofopioidsincludingduragesic nucyntaandnucyntaerandhavebeensubpoenaedbytwootherstatesforinformationrelatedtoopioid marketingpractices inmaysantaclaraandorangecountiesincaliforniafiledacomplaintinstatecourtinorangecountycalifornia againstnumerouspharmaceuticalmanufacturersincludingjjandjpiallegingclaimsrelatedtoopioidmarketing practicesincludingfalseadvertisingunfaircompetitionandpublicnuisancethecountiesseekinjunctiveandmonetary reliefinfebruarythedefendantsfiledmotionschallengingthesufficiencyofthecomplaintinaugustthe courtstayedthecaseuntilthefdaconcludesitsongoinginquiryintothesafetyandeffectivenessoflongtermopioid treatmentfollowingamotionbythecountiestoliftthestayinoctoberthecourtkeptthestayinplaceinpart requestedthepartiestoconferandadjournedthematteruntilalaterdate injunethecityofchicagofiledacomplaintincookcountycircuitcourtagainstthesamegroupof pharmaceuticalmanufacturersincludingjjandjpialleginganumberofclaimsrelatedtoopioidmarketingpractices includingconsumerfraudviolationsandfalseclaimsandseekinginjunctiveandmonetaryreliefthecasewaslater removedtotheunitedstatesdistrictcourtforthenortherndistrictofillinoisindecemberjjandjpifileda motiontodismissthecityofchicagosfirstamendedcomplaintwhichwasgrantedwithleavetofileanamended complaintthecityfiledasecondamendedcomplaintandinnovemberjjandjpifiledamotiontodismissthe secondamendedcomplaintinseptemberthecourtdismissedeightofthecitystencausesofactionandgranted thecityonefinalopportunitytorepleadthedismissedclaimsthecityfiledathirdamendedcomplaintinoctober andindecemberjjandjpifiledananswerastotwocausesofactionandamotiontodismisstheremaining causesofaction inseptemberthetennesseeattorneygeneraldivisionofconsumeraffairsissuedarequestforinformationtojpi andotherpharmaceuticalcompaniesrelatedtoopioidsmarketingpractices inaugustthenewhampshireattorneygeneralconsumerprotectionandantitrustbureauissuedasubpoenato jpiandotherpharmaceuticalcompaniesrelatedtoopioidsmarketingpracticesinoctoberthestatefiledamotion inthestateofnewhampshiresuperiorcourttoenforcethesubpoenajpiandtheotherpharmaceuticalcompanies subsequentlyfiledajointmotionforinjunctivereliefandaprotectiveordertoprecludethestatefromengagingprivate contingentfeecounseltoparticipateinthestatesinvestigationoranysubsequentenforcementactioninmarch thecourtgrantedtheprotectiveorderonthegroundsthatthestatehadnotobtainedrequisiteexecutiveandlegislative approvalstoretainprivatecounselbutrejectedthecontentionthatthecontingencyfeeagreementwasotherwise unlawfulallpartieshaveappealedthemarchrulingtothenewhampshiresupremecourtinaugustthe courtdeniedthepharmaceuticalcompaniesjointmotiontoenforcetheprotectiveorderonthegroundthattheunderlying deficiencylegislativeapprovalhadbeencuredinseptemberthestatestipulatedtostayenforcementofany subpoenaspendingthenewhampshiresupremecourtsconsiderationofthecompaniesappealofthemarch ruling indecemberthestateofmississippifiledacomplaintinthechancerycourtofthefirstjudicialdistrictofhinds countyagainstsubstantiallythesamegroupofpharmaceuticalmanufacturersasinthesuitsbroughtbythecalifornia countiesandcityofchicagoincludingjjandjpialleginganumberofclaimsrelatedtoopioidmarketingpracticesand seekingpenaltiesandinjunctiveandmonetaryreliefinmarchdefendantsfiledamotiontotransfervenueand motionstodismissthecomplaint inaugustthecountyofsuffolkinnewyorkfiledacomplaintagainstseveralpharmaceuticalmanufacturersin newyorksupremecourtincludingjjandjpiallegingclaimsrelatedtoopioidmarketingincludingclaimsbasedon deceptiveactsandpracticesfalseadvertisingfraudandunjustenrichmentthecomplaintseekspenaltiesandinjunctive andmonetaryrelief infebruarythecountyoferieandthecountyofbroomeinnewyorkeachfiledacomplaintinnewyorksupreme courtagainstseveralpharmaceuticalmanufacturersincludingjpibothcomplaintsallegeclaimsrelatedtoopioid marketingpracticesincludingstatutoryclaimsfordeceptiveactsandpracticesfalseadvertisingandviolationof newyorkssocialserviceslawandcommonlawcausesofactionforpublicnuisancefraudandunjustenrichment eachcountyisseekingcompensatoryandpunitivedamagesandcosts johnsonjohnsonannualreport inseptembersynthesincsynthesreceivedacivilinvestigativedemandissuedpursuanttothefalseclaimsact fromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathedemandsoughtinformationregarding allegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproductssyntheshas produceddocumentsandinformationinresponsetothedemandandiscooperatingwiththeinquiry inmayacclarentincacclarentreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrequestingdocumentsbroadlyrelatingtothesalesmarketingandallegedofflabelpromotionbyacclarent oftherelievastratusmicroflowspacerproducttherelievastratusspacerinmarchacclarent executedacivilsettlementwiththeunitedstatesjusticedepartmentandotheragenciestoresolvethisinvestigation johnsonjohnsonwasnotapartytothissettlementandtherewasnoadmissionofliabilityinaseparatematterinjuly theformerpresidentceoandvicepresidentofsalesofacclarenttheformeracclarentofficerswereconvicted ofmisdemeanorviolationsinconnectionwiththesaleandmarketingoftherelievastratusspacerthereareno chargesagainstacclarentethiconincorjohnsonjohnsoninthismatter inaugustdepuyorthopaedicsincdepuyincnowdepuysynthesincandjohnsonjohnsonservicesinc receivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictofmassachusettsandthecivil divisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionofmaterialsrelatingtothe depuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrictcourtforthedistrictof massachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaimsactagainstthe companiesinfebruarythedistrictcourtgrantedthecompaniesmotiontodismisswithprejudiceunsealedthe quitamcomplaintanddeniedthequitamrelatorsrequestforleavetofileafurtheramendedcomplaintthequitam relatorsappealedthecasetotheunitedstatescourtofappealsforthefirstcircuitthefirstcircuitsdecisioninthe caseispendingsinceoctoberagroupofstateattorneysgeneralhaveissuedcivilinvestigativedemands relatingtothedevelopmentsalesandmarketingofseveralofdepuyorthopaedicsincshipproductsthestatesare seekingmonetaryandinjunctivereliefinjulytheoregondepartmentofjusticewhichwasinvestigatingthese mattersindependentlyoftheotherstatesannouncedasettlementofitsasrxlhipdeviceinvestigationforatotal paymentofmilliontothestateoforegon inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconjohnsonjohnsonandethiconhavesinceenteredintoaseries oftollingagreementswiththestatesandthedistrictofcolumbiaparticipatinginthemultistateinvestigationandhave respondedtocivilinvestigativedemandsservedbycertainoftheparticipatingstatesthestatesareseekingmonetary andinjunctivereliefinmaycaliforniaandwashingtonfiledcivilcomplaintsagainstjohnsonjohnsonandethicon allegingviolationsoftheirconsumerprotectionstatutesinaugustkentuckyfiledasimilarcomplaintagainstthe companiesjohnsonjohnsonandethiconhaveenteredintoanewtollingagreementwiththeremainingstatesand thedistrictofcolumbia indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtssystemduringtheperiodtothepresenttheunited statesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelatetothe investigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuaryand ocdwasdivestedinjunefollowingthedivestitureofocdjohnsonjohnsonretainsocdsportionofany liabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakosinmarchand marchtheunitedstatesattorneysofficerequestedthatjohnsonjohnsonproducecertaindocumentsand johnsonjohnsoniscooperatingwiththerequests injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhinds countymississippiagainstjohnsonjohnsonandjohnsonjohnsonconsumercompaniesincnowjohnson johnsonconsumerincjjcithecomplaintallegesthatdefendantsfailedtodiscloseallegedhealthrisksassociated withfemaleconsumersuseoftalccontainedinjohnsonsbabypowderandjohnsonsshowertoshower aproductnolongersoldbyjjciandseeksinjunctiveandmonetaryreliefthismatteriscurrentlyscheduledfortrialin september inmarchjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstates attorneysofficeforthesoutherndistrictofnewyorkrelatedtojpiscontractualrelationshipswithpharmacybenefit johnsonjohnsonannualreportmanagersovertheperiodfromjanuarytothepresentwithregardtocertainofjpispharmaceuticalproductsthe demandwasissuedinconnectionwithaninvestigationunderthefalseclaimsact injanuaryjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandcidfromtheunitedstates departmentofjusticedojrelatingtoallegationsconcerningthesalesandmarketingpracticesofolysiotmjpiis cooperatingwithdojinappropriatelyrespondingtothecid infebruaryjohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingtheproductionofrecordspertainingtopaymentstoanyccharitableorganizationthat providesfinancialassistancetomedicarepatientsmultiplepharmaceuticalcompanieshavepubliclyreportedreceiptof similarsubpoenasandongoinginquiries inrecentyearsjohnsonjohnsonhasreceivednumerousrequestsfromavarietyofunitedstatescongressional committeestoproduceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsonto cooperatewiththeseinquiriesbyproducingtherequestedinformation generallitigation injunefollowingthepublicannouncementthatorthoclinicaldiagnosticsincocdhadreceivedagrandjury subpoenafromtheunitedstatesdepartmentofjusticeantitrustdivisioninconnectionwithaninvestigationthathas sincebeenclosedmultipleclassactioncomplaintswerefiledagainstocdbydirectpurchasersseekingdamagesfor allegedpricefixingthesecaseswereconsolidatedforpretrialpurposesintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaasinrebloodreagentantitrustlitigationinaugustthedistrictcourtgranteda motionfiledbytheplaintiffsforclasscertificationinapriltheunitedstatescourtofappealsforthethirdcircuit reversedtheclasscertificationrulingandremandedthecasetothedistrictcourtforfurtherproceedingsinoctober thedistrictcourtagaingrantedthemotionbytheplaintiffsforclasscertificationinjulyocdfiledamotion forsummaryjudgmentocdwasdivestedinandjohnsonjohnsonretainedanyliabilitythatmayresultfromthese cases inseptemberjohnsonjohnsonjohnsonjohnsonincandmcneilconsumerhealthcaredivisionofjohnson johnsonincreceivedanoticeofcivilclaimfiledbynickfieldinthesupremecourtofbritishcolumbiacanadathe bccivilclaimthebccivilclaimisaputativeclassactionbroughtonbehalfofpersonswhoresideinbritishcolumbia andwhopurchasedduringtheperiodbetweenseptemberandinoraboutdecemberoneormorevarious mcneilinfantsorchildrensoverthecountermedicinesthatweremanufacturedatthefortwashingtonpennsylvania facilitythebccivilclaimallegesthatthedefendantsviolatedthebcbusinesspracticesandconsumerprotectionact andothercanadianstatutesandcommonlawsbysellingmedicinesthatwereallegedlynotsafeandoreffectiveordid notcomplywithcanadiangoodmanufacturingpracticestheclasscertificationhearingscheduledforoctober wasadjournedandthereiscurrentlynodatesetforthathearing inmaytwopurportedclassactionswerefiledinfederalcourtoneintheunitedstatesdistrictcourtforthecentral districtofcaliforniaandoneintheunitedstatesdistrictcourtforthesoutherndistrictofillinoisagainstjohnson johnsonjjandjohnsonjohnsonconsumercompaniesincnowjohnsonjohnsonconsumerincjjcialleging violationsofstateconsumerfraudstatutesbasedonnondisclosureofallegedhealthrisksassociatedwithtalccontained injohnsonsbabypowderandjohnsonsshowertoshoweraproductnolongersoldbyjjcibothcases seekinjunctivereliefandmonetarydamagesneitherincludesaclaimforpersonalinjuriesinoctoberbothcases weretransferredtotheunitedstatesdistrictcourtforthedistrictcourtofnewjerseyaspartofanewlycreatedfederal multidistrictlitigationindecemberjjandjjcifiledamotiontodismissoneofthecases inaugustunitedstatescustomsandborderprotectionuscbpissuedapenaltynoticeagainstjanssenortho llcjanssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolatetheactive pharmaceuticalingredientinprezistainconnectionwithitsimportationintotheunitedstatesinoctober janssenorthosubmittedapetitionforreliefinresponsetothepenaltynoticeinmayuscbpissuedan amendedpenaltynoticeassessingsubstantialpenaltiesandjanssenorthofileditspetitionforreliefinjuly inmarchandapriloverputativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourts aroundtheunitedstatesagainstjohnsonjohnsonvisioncareincjjvciothercontactlensmanufacturers distributorsandretailersallegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlensesthe complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailers concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumerstheplaintiffsareseekingdamagesand injunctivereliefalloftheclassactioncasesweretransferredtotheunitedstatesdistrictcourtforthemiddledistrictof johnsonjohnsonannualreport floridainjunetheplaintiffsfiledaconsolidatedclassactioncomplaintinnovemberandindecember jjvciandotherdefendantsfiledmotionstodismissinjunethecourtdeniedthemotionstodismiss discoveryisongoing inapriljohnsonjohnsonvisioncareincjjvcifiledacomplaintintheunitedstatesdistrictcourtforthe districtofutahagainstthestateofutahseekingadeclaratoryjudgmentthatalawpassedbythestatetobanunilateral pricingpoliciessolelyinthecontactlensmarketviolatesthecommerceclauseoftheunitedstatesconstitutionthe courtdeniedjjvcismotionforapreliminaryinjunctionjjvciappealedargumentontheappealwasheldinaugust indecembertheappellatecourtdeniedjjvcisappeal inapriladimmunecorporationltdadimmunecommencedanarbitrationintheinternationalcourtofarbitration internationalchamberofcommerceagainstcrucellswitzerlandagnowjanssenvaccinesagandcrucellholland bvnowjanssenvaccinespreventionbvcollectivelycrucelladimmuneclaimsthatcrucellbreachedcertain agreementsrelatingtothesupplyoffluantigenwhencrucellceasedpurchasingfluantigenfromadimmuneindecember adimmunefileditsstatementofclaimseekingmonetarydamagesthearbitrationhearingtookplaceinnovember andthepartiesareawaitingaruling inaugusttwothirdpartypayorsfiledapurportedclassactionintheunitedstatesdistrictcourtfortheeastern districtoflouisianaagainstjanssenresearchdevelopmentllcjanssenorthollcjanssenpharmaceuticalsinc orthomcneiljanssenpharmaceuticalsincandjohnsonjohnsonaswellascertainbayerentitiesallegingthatthe defendantsimproperlymarketedandpromotedxareltoassaferandmoreeffectivethanlessexpensivealternative medicationswhilefailingtofullydiscloseitsrisksthecomplaintseeksdamagesinanunspecifiedamount johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation restructuring thecompanyannouncedrestructuringactionsinitsmedicaldevicessegmenttobetterservetheneedsofpatientsand customersintodaysevolvinghealthcaremarketplacethecompanyisundertakingactionstostrengthenitsgotomarket modelacceleratethepaceofinnovationfurtherprioritizekeyplatformsandgeographiesandstreamlineoperationswhile maintaininghighqualitystandards thecompanyestimatesthatinconnectionwithitsplansitwillrecordpretaxrestructuringrelatedchargesof approximatelybilliontobillioninthecompanyrecordedapretaxchargeofmillionofwhich millionwasincludedincostofproductssoldandmillionwasincludedinotherincomeexpenseseetablebelow foradditionaldetailstotalprojectcostsofbillionhavebeenrecordedsincetherestructuringhasbeen announced additionallyaspartoftheplanthecompanyexpectsthattherestructuringactionswillresultinpositioneliminationsof approximatelytopercentofthemedicaldevicessegmentsglobalworkforceoverthenexttwoyearssubjecttoany consultationproceduresincountrieswhererequiredapproximatelypositionshavebeeneliminatedsincethe restructuringwasannounced thecompanyestimatesthatapproximatelyonehalfofthecumulativepretaxcostswillresultincashoutlaysincluding approximatelymillionofemployeeseveranceapproximatelyonehalfofthecumulativepretaxcostsarenoncash relatingprimarilytofacilityrationalizationinventorywriteoffsandintangibleassetwriteoffs johnsonjohnsonannualreportthefollowingtablesummarizestheseverancechargesandtheassociatedspendingunderthisinitiativethroughthefiscal yearended dollarsinmillions severance assetwriteoffs total restructuringcharge activity reservebalancejanuary currentyearactivity charges cashpayments settlednoncash reservebalancejanuary cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextmonthsinaccordancewiththecompanysplans andlocallaws otherincludesprojectexpensesuchassalariesforemployeessupportingtheinitiativeandconsultingexpenses johnsonjohnsonannualreport report independent registered public accounting firm totheshareholdersandboardofdirectorsofjohnsonjohnson inouropiniontheaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowspresentfairlyinallmaterialrespectsthefinancialpositionof johnsonjohnsonanditssubsidiariesatjanuaryandjanuaryandtheresultsoftheiroperationsand theircashflowsforeachofthethreeyearsintheperiodendedjanuaryinconformitywithaccountingprinciples generallyacceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespects effectiveinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadwaycommission cosothecompanysmanagementisresponsibleforthesefinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthesefinancialstatementsandonthecompanysinternalcontroloverfinancialreportingbasedon ourintegratedauditsweconductedourauditsinaccordancewiththestandardsofthepubliccompanyaccounting oversightboardunitedstatesthosestandardsrequirethatweplanandperformtheauditstoobtainreasonable assuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementandwhethereffectiveinternalcontrol overfinancialreportingwasmaintainedinallmaterialrespectsourauditsofthefinancialstatementsincludedexamining onatestbasisevidencesupportingtheamountsanddisclosuresinthefinancialstatementsassessingtheaccounting principlesusedandsignificantestimatesmadebymanagementandevaluatingtheoverallfinancialstatement presentationourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinions asdiscussedinnotetotheconsolidatedfinancialstatementsthecompanychangedthemannerinwhichitaccounts forandpresentscertainelementsofsharebasedpaymentsin acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statements becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate spricewaterhousecoopersllp florhamparknewjersey february johnsonjohnsonannualreportmanagements report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciples internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofjanuaryinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof januarythecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofjanuaryhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappears herein salexgorsky sdominicjcaruso alexgorsky dominicjcaruso chairmanboardofdirectors executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreport shareholder return performance graphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreportitem changes disagreements accountants accounting financial disclosure notapplicable item controls procedures disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecisions regardingrequireddisclosurealexgorskychairmanandchiefexecutiveofficeranddominicjcarusoexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsgorsky andcarusoconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendedjanuarytherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreporting thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item b information notapplicable johnsonjohnsonannualreport part iii item directors executive officers corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandstockownershipandsectioncompliancesectionabeneficialownershipreporting complianceintheproxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiof thisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteat wwwjnjcomcodeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequestto thesecretaryatthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconduct oranywaiverofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbe postedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsite foratleastoneyear inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficers isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationcompensationcommitteereportcompensationdiscussionand analysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationcommitteereportinthe proxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeemedincorporatedby referenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactofas amendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitbyreference item security ownership certain beneficial owners management related stockholder matters theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitemstock ownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplansand stockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreportequity compensation plan information thefollowingtableprovidescertaininformationasofjanuaryconcerningthesharesofthecompanyscommon stockthatmaybeissuedunderexistingequitycompensationplans numberof securitiesto beissuedupon weightedaverage numberofsecurities exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandrights optionsandrights compensationplans equitycompensationplansapprovedbysecurity holders equitycompensationplansnotapprovedbysecurity holders total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholders longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoptions andrights thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationships related transactions director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpartytransactionsintheproxystatement item principal accountant fees services theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreport part iv item exhibits financial statement schedules thefollowingdocumentsarefiledaspartofthisreport financialstatements consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornotes exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyhas electednottoincludesuchsummaryinformation johnsonjohnsonannualreportsignatures pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorized datefebruary johnsonjohnson registrant sagorsky agorskychairmanboardofdirectors andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowing personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated signature title date sagorsky chairmanboardofdirectors february agorsky chiefexecutiveofficer principalexecutiveofficer sdjcaruso chieffinancialofficer february djcaruso principalfinancialofficer srakapusta controllerandchiefaccountingofficer february rakapusta principalaccountingofficer smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis smbmcclellan director february mbmcclellan sammulcahy director february ammulcahy swdperez director february wdperez scprince director february cprince saewashington director february aewashington srawilliams director february rawilliams johnsonjohnsonannualreport exhibit index regsk exhibittable itemno descriptionofexhibit restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary ii bylawsofthecompanyasamendedeffectivejanuaryincorporatedhereinbyreferencetoexhibitthe registrantsformkcurrentreportfiledjanuary upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedwiththecommissiononmayfileno b formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformk currentreportfiledjanuary c longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledwith thecommissiononmarch formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportfiledmay e executiveincentiveplanasamendedincorporatedhereinbyreferencetoexhibitfoftheregistrantsformkannual reportforthefiscalyearendeddecember f domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember g amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember h certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrantsform qquarterlyreportforthequarterendedseptember amendedandrestateddeferredfeeplanfordirectorsincorporatedhereinbyreferencetoexhibitkoftheregistrants formkannualreportforthefiscalyearendedjanuary j executiveincomedeferralplanamendedandrestatedincorporatedhereinbyreferencetoexhibitoftheregistrants formqquarterlyreportforthequarterendedseptember k excesssavingsplanincorporatedhereinbyreferencetoexhibitjoftheregistrantsformkannualreportforthe fiscalyearendeddecember l amendmentstothejohnsonjohnsonexcesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreference toexhibitpoftheregistrantsformkannualreportforthefiscalyearendeddecember excessbenefitplansupplementalretirementplanincorporatedhereinbyreferencetoexhibithoftheregistrantsform kannualreportforthefiscalyearendedjanuary n amendmentstotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitroftheregistrantsformkannualreportforthefiscalyearended december amendmenttotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitqoftheregistrantsformkannualreportforthefiscalyearended december p executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary q executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch r johnsonjohnsonretirementsavingsplanjohnsonjohnsonsavingsplanforunionrepresentedemployeesandjohnson johnsonsavingsplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformsfiledwith thecommissiononmay employmentagreementfordrpaulusstoffelsincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedseptember summaryofemploymentarrangementsforsandraepetersonincorporatedhereinbyreferencetoexhibittofthe registrantsformkannualreportfortheyearendeddecember johnsonjohnsonannualreportu severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterended september v firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportfor thequarterendedjune w secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary statementofcomputationofratioofearningstofixedchargesfiledwiththisdocument subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument b certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument b certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument xbrlextensiblebusinessreportinglanguagethefollowingmaterialsfromthisreportforthefiscalyearendedjanuary formattedinextensivebusinessreportinglanguagexbrliconsolidatedbalancesheetsiiconsolidated statementsofearningsiiiconsolidatedstatementsofcomprehensiveincomeivconsolidatedstatementsofequityv consolidatedstatementsofcashflowsandvinotestotheconsolidatedfinancialstatements managementcontractorcompensatoryplan acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompany thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthisannual report exhibit exhibit exhibit johnsonjohnsonannualreport thispageintentionallyleftblankexhibita certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ialexgorskycertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrols andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedures tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporting salexgorsky alexgorsky chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibitb certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact idominicjcarusocertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrols andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedures tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporting sdominicjcaruso dominicjcaruso chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibita certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedalexgorskythechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany salexgorsky alexgorsky chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportexhibitb certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersigneddominicjcarusothechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany sdominicjcaruso dominicjcaruso chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankreconciliationofnongaapfinancialmeasures incr dollarsinmillionsexceptpersharedata decr earningsbeforeprovisionfortaxesonincomeasreported intangibleassetamortizationexpense restructuringother litigationexpensenet depuyasrtmhipprogram inprocessresearchanddevelopment earningsbeforeprovisionfortaxesonincomeasadjusted netearningsasreported intangibleassetamortizationexpense restructuringother litigationexpensenet depuyasrtmhipprogram inprocessresearchanddevelopment netearningsasadjusted dilutednetearningspershareasreported intangibleassetamortizationexpense restructuringother litigationexpensenet depuyasrtmhipprogram inprocessresearchanddevelopment dilutednetearningspershareasadjusted operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rates impactofcurrencyatforeigncurrencyexchangerates operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rates includesmillionrecordedincostofproductssoldandmillionrecordedinotherincomeexpenseinand millionrecordedincostofproductssoldin thecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsandnetearningspersharedilutedon anadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestorsamongother thingsthesemeasuresmayassistinvestorsinevaluatingthecompanysresultsofoperationsperiodoverperiodin variousperiodsthesemeasuresmayexcludesuchitemsasintangibleassetamortizationexpensesignificantcosts associatedwithacquisitionsrestructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificant accountingortaxmattersthesespecialitemsmaybehighlyvariabledifficulttopredictandofasizethatsometimeshas substantialimpactonthecompanysreportedresultsofoperationsforaperiodmanagementusesthesemeasures internallyforplanningforecastingandevaluatingtheperformancesofthecompanysbusinessesincludingallocating resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovision fortaxesonincomenetearningsandnetearningspersharedilutedpreparedinaccordancewithgaapadjusted earningsbeforeprovisionfortaxesonincomeadjustednetearningsandadjustednetearningspersharedilutedmaynot becomparablewiththecalculationofsimilarmeasuresforothercompaniesthelimitationsofusingthesenongaap financialmeasuresasperformancemeasuresarethattheyprovideaviewofthecompanysresultsofoperationswithout includingalleventsduringaperiodsuchasintangibleassetamortizationexpensetheeffectsofanacquisitiontheortho clinicaldiagnosticsdivestiturerestructuringlitigationandchangesinapplicablelawsandregulationsincluding significantaccountingortaxmattersanddonotprovideacomparableviewofthecompanysperformancetoother companiesinthehealthcareindustryinvestorsshouldconsidernongaapfinancialmeasuresinadditiontoandnotas replacementsfororsuperiortomeasuresoffinancialperformancepreparedinaccordancewithgaap johnsonjohnsonannualreportboard directors senior management alexgorsky alexgorsky chairmanboardofdirectors chiefexecutiveofficer chairmanexecutivecommittee marycbeckerle chiefexecutiveofficeranddirector dominicjcaruso huntsmancancerinstituteattheuniversityofutah executivevicepresidentchieffinancialofficer distinguishedprofessorofbiology collegeofscienceuniversityofutah joaquinduato executivevicepresidentworldwidechairmanpharmaceuticals dscottdavis formerchairmanandchiefexecutiveofficer petermfasolo unitedparcelserviceinc executivevicepresidentchiefhumanresourcesofficer ianeldavis ronaldakapusta chairmanrollsroyceholdingsplc corporatecontroller formerchairmanandworldwidemanagingdirector chiefaccountingofficer mckinseycompany ashleymcevoy markbmcclellan companygroupchairmanconsumermedicaldevices directordukerobertjmargolismd jorgemesquita centerforhealthpolicy executivevicepresidentworldwidechairmanconsumer annemmulcahy sandraepeterson formerchairmanandchiefexecutiveofficer executivevicepresidentgroupworldwidechairman xeroxcorporation garyjpruden williamdperez executivevicepresidentworldwidechairmanmedicaldevices retiredpresidentandchiefexecutiveofficer wmwrigleyjrcompany michellerryan treasurer charlesprince retiredchairmanandchiefexecutiveofficer michaelesneed citigroupinc worldwidevicepresidentglobalcorporateaffairs chiefcommunicationsofficer aeugenewashington dukeuniversityschancellorforhealthaffairs thomasjspellmaniii presidentandchiefexecutiveofficer corporatesecretary dukeuniversityhealthsystem assistantgeneralcounsel ronaldawilliams paulusstoffels formerchairmanandchiefexecutiveofficer executivevicepresidentchiefscientificofficer aetnainc jennifertaubert companygroupchairmanpharmaceuticalstheamericas michaelhullmann executivevicepresidentgeneralcounsel kathrynewengel worldwidevicepresidentjohnsonjohnsonsupplychain memberexecutivecommittee johnsonjohnsonannualreportprincipaloffice stocklisting johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock ourwebsitewwwjnjcom newbrunswicknewjersey listedonnewyorkstockexchange stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholders shareholderrelationscontact thursdayapril thomasjspellmaniii wwwfacebookcomjnj corporatesecretary ameasterndoorsopenatam statetheatre wwwtwittercomjnjcares livingstonavenue investorrelationscontact wwwtwittercomjnjnews newbrunswicknewjersey josephjwolk allshareholdersasoftherecorddateof vicepresidentinvestorrelations wwwyoutubecomjnj februaryareinvitedtoattend aformalnoticeofannualmeeting httpwwwlinkedincomcompany johnsonjohnson proxystatementandproxyhavebeen investorrelationswebsite madeavailabletoshareholders wwwinvestorjnjcom thejohnsonjohnsonyearin annualreportonformkand stocktransferagentandregistrar reviewisavailableonourwebsiteat proxystatement questionsregardingstockholdings wwwyearinreviewjnjcom johnsonjohnsonsannualreportonformk certificatereplacementtransferdividends theinformationonthesewebsitesshould forthefiscalyearendedjanuaryis andaddresschangesshouldbedirectedto notbedeemedtobepartofthisannual includedinthisannualreportinitsentiretywith ourstocktransferagentandregistrarat report theexceptionofcertainexhibitstheformk computersharetrustcompanyna completewithallofitsexhibitsisavailableonour pobox websiteatwwwinvestorjnjcomseccfmandthe collegestationtx secswebsiteatwwwsecgov overnightmail shareholdersmayalsoobtaincopiesofthe computersharetrustcompanyna exhibitsourannualreporton qualitycirclesuite formkandourproxystatement collegestationtx withoutchargeuponwrittenrequesttothe officeofthecorporatesecretaryatour shareholderwebsite principalofficeaddressorbycalling wwwcomputersharecominvestor dividendreinvestmentplan electronicdeliverynotification theplanallowsforfullorpartialdividend theproxystatementandourannual reinvestmentandadditionalweeklycash reportareavailableonourwebsite investmentsuptoperyearin wwwinvestorjnjcomgov johnsonjohnsoncommonstockwithout annualmeetingmaterialscfmshareholderswho pershareorservicechargesonstock c receivepapercopiesofourproxystatementand purchasesifyouareinterestedin annualreportbymailcanelecttoreceiveinstead participatingintheplanandneedan anemailmessagewithalinktothosedocuments enrollmentformandormoreinformation ontheinternetregisteredshareholdersmay pleasecalltheplanadministrator thejohnsonjohnsonannualreport enrollinelectronicdeliveryat computersharetrustcompanynaat containsmanyofthevaluabletrademarks wwwcomputersharenacomgreenbeneficial andtradenamesownedandusedbythe shareholderswhoholdsharesofjohnson outsidetheusoraccessonlineat johnsonjohnsonfamilyofcompaniesin johnsoncommonstockthroughabankbrokeror wwwcomputersharecominvestor theunitedstatesandinternationallyto otherholderofrecordgenerallycanenrollfor distinguishproductsandservicesof electronicdeliveryatenrollicsdeliverycomjnj hearingimpaired outstandingquality shareholderswhohaveinquiriesregarding johnsonjohnson stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheuscaring world one person time inspires unites people